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Minimally invasive procedures are replacing a variety of open surgeries 
as medical technologies advance. Thanks to the limited incision 
technique, many patients have been able to avoid suffering from 
inflammation, complications, and long recovery time. Highly sensitive 
imaging modalities and probes can help clinicians to identify the 
operation site, while tissue adhesives and sealants can promote wound 
closure. The cell-based therapy is considered as an alternative to surgery 
or organ transplantation, in which the cells are labeled with imaging 
probes to enable tracking and visualization of their therapeutic function. 
Nanoparticles are the ideal candidates for imaging probes that offer high 
contrast enhancement and biocompatibility. Modifying the surface of 
nanoparticles to enhance their adhesion to cells and biological tissues 
allows efficient cell labeling and closure of internal wound for 
therapeutic purposes. 
Following the Introduction chapter, Chapter 2 describes the 
development of multifunctional adhesives for minimally invasive 
procedures. By modifying their surface with silica, tantalum oxide 
nanoparticles can strongly adhere to biological tissues and provide 
contrast enhancement effects for real-time imaging modalities including 
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X-ray fluoroscopy, X-ray computed tomography, ultrasonography, and 
fluorescence imaging. The thin silica coating allows the tantalum oxide 
nanoparticles to be dispersed stably and to adhere to substrates with a 
force that is comparable to clinically employed cyanoacrylate-based 
adhesives. Moreover, these nanoparticles overcome the limitations of 
cyanoacrylate such as cytotoxicity and induction of inflammation, and 
are thus more suitable for intracorporeal use in minimally invasive 
procedures. Real-time image-guided procedures, immediate sealing of 
puncture wounds in liver and marking of tumor, are demonstrated using 
surface-modified tantalum oxide nanoparticles in animal experiments. 
In Chapter 3, I present a simple method for efficient labeling of 
therapeutic cells with multifunctional nanoparticles. Disulfide bonds in 
cell membrane proteins are reduced to active thiol groups, and the 
mesoporous silica nanoparticles (MSN) with maleimide group are used 
to coat mammalian cells via chemical conjugation. The fluorophore-
labeled mesoporous silica nanoparticles allow tracking of the coated 
cells and their visualization were done by intra-vital microscopy. Drug 
molecules can be loaded into the mesoporous silica nanoparticles for 
local delivery through cell implantation. Furthermore, the activities of 
iv 
 
injected cells can be enhanced via conjugation of immunosuppressant-
loaded MSNs and polymers to overcome innate immune rejection. 
Keywords: nanoparticle, biomedical application, minimally invasive 
procedures, tissue adhesive, cell surface engineering 
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Chapter 1. Introduction: 
Cell- and Tissue-Adhesive Nanoparticles, and their 
Applications to Minimally Invasive procedures 
 
1.1 Introduction 
Nanoparticles (NPs) have been extensively studied for various 
biomedical applications. Their applicability to various biomedicine 
fields is broadened by unique physical properties that are attributable to 
their inorganic crystal structure, large surface area, and extremely small 
sizes.[1,2] NPs are particularly useful for cancer diagnosis and therapy: 
they can target tumors due to their enhanced permeation and retention 
(EPR) effect and drug-loading capacity.[3] Their unique physical 
properties ensure a strong signal for an efficient contrast effect in cancer 
imaging.[4-9] The surface structure of NPs can be modified by functional 
molecules. For example, attaching fluorescent dyes or chelating ligands 
confers an additional contrast effect, whereas conjugation with specific 
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ligands or antibodies provides a targeting capability. [10,11] NPs can be 
designed to have both diagnostic and therapeutic functions[12-15] for the 
applications in cancer treatment. Exploitation of the catalytic 
nanomaterials allows the modulation of reactive oxygen species and the 
control of cell signaling, enabling their applications to regenerative 
medicine. [16-19] 
One of the biomedical applications of multifunctional NPs is 
minimally invasive procedure.[20,21] Strong contrast enhancement with 
high sensitivity enables the visualization of the NPs distributed 
throughout the body, providing accurate spatiotemporal information for 
minimally invasive procedures.[22] In addition, their efficient thermal 
conversion of light energy as well as inducible drug release are useful for 
the treatment of remote areas. 
Many studies have examined the interface between biological 
environment and NP surface to maximize the applicability of NPs in the 
medical applications. NPs form colloids of various materials in 
dispersive media, while physiological environments consist of a variety 
of biological molecules in water. Interactions among them can be 
understood in terms of adhesion and adsorption. Many recent studies 
3 
investigated the interactions between nanomaterials and serum proteins. 
NPs encounter serum proteins upon systemic administration, and 
adsorption occurs before NPs reaching receptors in target tissues. 
Cellular uptake is governed by the interaction/adhesion of NPs to cell 
membrane proteins.[23] The biodistribution of NPs depends on their 
interaction with immune cells, that is, their uptake by macrophages or 
binding to receptors in target tissues. Therefore, optimization of the 
adhesion and adsorption interactions between the NP surface and 
biological molecules, cells, and tissue is necessary to broaden the 




1.2 Nanomaterial adhesion in biological systems 
Nanomaterial surface has a much higher free energy than that of bulk 
material. Therefore, the large surface area of NPs is useful for selective 
adsorption of biomolecules as NPs contact biological fluids.[24] Although 
the stealth effect of NPs can be derived from the modification of their 
surface with polymers such as polyethylene glycol (PEG). The active NP 
surface is usually covered with biomolecules that spontaneously adhere 
and alter the surface properties of the NPs.[25] Thus, the adhesion of 
biomolecules onto the NP surface influences the interaction between NPs 
and cells or administered tissues. The nonspecific adhesion of 
biomolecules due to high free energy can be modulated by coating NPs 
with polymers,[26] or transformed into a specific interaction by 
functionalizing of the NP surface with specific targeting ligands or 
proteins. 
High free energy of the NP surface can promote NP adsorption 
onto cell surface and efficient cellular uptake, which are influenced by 
various factors including particle size, morphology, surface charge, and 
surface modification.[25] A recent study reported that surface free energy 
can be exploited to increase NP adhesion to biological tissues.[27] In this 
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section, I describe factors that influence the interactions between NPs 
and cells and tissues. In this context, I also discuss various applications 
that depend on the modulation of interactions between NPs and 
biomolecules. 
 
1.2.1 Adhesion of nanoparticles on cell surface 
Adhesion of molecules to substrate or between distinct substrates is a 
complex phenomenon because it often involves combinations of 
multiple interactions: molecular adsorption, electromagnetic attraction, 
diffusional entanglement, and mechanical force.[28,29] Surface 
contamination, substrate roughness, and friction are also factors that 
affect the adhesion properties. In the case of the adhesion between 
biological molecules and NPs, however, the adhesion properties of NPs 
are governed by fewer mechanisms. Adhesion strength is minimally 
affected by mechanical force due to the small size of NPs. The adhesion 
derived from of the diffusion of polymeric chains into substrates, which 
polymer-based adhesives have, can be excluded in colloidal NP-based 
adhesives. Colloidal NPs interact with biomolecules only through 
hydrophobic/Coulombic interactions and hydrogen bonding.  
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1.2.2 NP attachment to cells 
The interaction between NPs and cells is governed by the NP surface 
characteristics such as surface charge, polymer density, and nature of the 
inorganic NPs.[30] Because NPs are mainly internalized into the cells 
through endocytosis;[31] their initial adhesion or binding to cells is critical 
for this process (Figure 1.1). The rate of NP uptake by cells depends on 
the amount of NPs that adhere to the cell surface.[32] The adhered NPs 
can enter cells through energy-dependent intake or energy-independent 
insertion. Endocytosis includes clathrin- and caveolae-mediated 
pathways, phagocytosis, and macropinocytosis.[23] 
The surface characteristics of NPs play a key role in the 
interaction between NPs and cells. For biomedical applications, NPs 
must be well dispersed in physiological media such as water or saline at 
neutral pH. An electrical double layer and electrostatic repulsive force 
are frequently used to achieve colloidal stability. Carboxylates, amine, 
sulfate, or zwitterionic ligands contribute to the stable dispersion of NPs. 
Polymers are also frequently-used coating materials to create a sterically 
repulsive layer on NP surface. PEG-based non-ionic surfactants are used 
as stabilizing agents for NPs in aqueous media.[33-40] 
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The distinct electrostatic and electrodynamic properties of NPs 
conferred by surface potential and capping ligands modulate their 
interactions with cells. Most animal cells have a negatively charged 
surface that preferentially attracts positively charged NPs. The effective 
surface charge density of NPs determines their electrostatic interaction 
with cells (Figure 1.2);[41] this applies to quantum dots and gold, silica, 
and magnetic NPs.[42] Atomic force microscopy observations have 
confirmed that positively charged NPs can adhere to the cellular 
surface.[44] Although attachment of serum proteins can change their zeta 
potential from −40 to −20 mV [43], this does not affect NP internalization 
(Figure 1.3).[41] Cytotoxicity is also influenced by interaction of NPs 
with the cell membrane during uptake.[45] Neutral or negatively charged 
NPs can also attach to the cell surface in the absence of PEG or serum in 
the medium.[46] 
Although generally positively charged NPs adhere to the cell 
membrane, this does not apply to the neuronal surface, which attract only 
negatively charged NPs at the synaptic cleft. This is because neurons in 
the resting state have a positively charged outer surface. Depolarization 
creating an action potential transiently alters the counterions surrounding 
negatively charged NPs, resulting in a stable electrostatic interaction 
8 
between the negatively charged NPs and the positively charged outer 
surface of the neuronal membrane.[47] 
Target-specific biomolecules can also modulate NP adhesion and 
internalization. For instance, antibodies or their fragments, targeting 
peptides, and folic acid, which can interact with the specific receptors, 
can enhance NP adhesion to the cell surface.[48] Although targeting 
ligands alter the rate of NP internalization, serum proteins can non-
specifically adhere to the NP surface, forming a protein corona that may 
block the active targeting moiety[49] and NP adsorption to the cell 
membrane. The amount of NPs that adhere to cells can be altered by 
incubation in serum-free medium, as observed for silica and polystyrene 
NPs.[46] 
Chemical modification of the NP surface can promote adhesion 
of NPs to cells. Thiol groups on the T cell, B cell, and hematopoietic 
stem cell surface enable attachment of liposome NPs to the cell surface 
through a strong covalent bonding (Figure 1.4).[50] 
 The attraction of the NPs with cells can control the adhesion of 
cells onto substrate by coating plain substrate with NPs. Such an 
approach has been used in the preparation of a solid scaffold for tissue 
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regeneration; additionally, various biocompatible nanomaterials have 
been incorporated onto implant surfaces.[51] NP adhesion onto the cell 
surface can also be used as nanostickers that promote the formation of 
cell-NP hybrid aggregates. The cells adhere to each other through 
homotypic interactions between membrane proteins known as cadherins; 






Figure 1.1. Adhesion of 40-nm phosphatidyl serine-COOH NPs onto the 
A549 cell membrane, as determined by flow cytometry. (a, b) Schematic 
illustration of the procedures used to measure NP adhesion to the cell 
membrane. (c, d) Experimental data showing the amount of adsorbed NP 
as a function of time under serum-free conditions (c) and in complete 





Figure 1.2. Schematic illustration of the interactions between cells and 
NPs with different types of surface charge. (A) Neutral and negatively 





Figure 1.3. Electrostatic attraction between NPs and cells. (a, b) 
Schematic illustration depicting how protein-bound gold nanoparticles 
(GNPs) attach to cells. (c) Surface charge density (SCD) based on ligand 
quantification. (d) Cellular uptake of the GNP array by HeLa cells with 




Figure 1.4. Stable conjugation of NPs to the surface of T cells and 
hematopoietic stem cells (HSCs) via cell-surface thiols. (a) Schematic 
illustration of maleimide-based conjugation to cell surface thiols. (b) 
Confocal micrographs of clusters of differentiation 8+ effector T cells 
and Sca-1+c-Kit+ HSCs immediately after conjugation with fluorescent 
1,1-dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine-labeled 
multilamellar lipid NPs (left) and after 4 days of in vitro expansion 
(right). Scale bars = 2 μm.  
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1.2.3 Adhesion of NPs to biological tissue 
NP interactions with biological tissue are chemically and 
physically complex. Intravenously delivered NPs are removed from the 
blood via renal clearance, uptake by macrophages, and the 
reticuloendothelial system. The interaction of NPs with biological tissue 
occurs within a confined environment; however, the adherence of 
biomolecules to NPs due to high free energy prevents the direct 
observation of this interaction, as confirmed by studies on the interaction 
of NPs in hydrogel, which has similar properties to biological tissue.[53] 
Interestingly, it was reported that NP solution can act as an adhesive for 
hydrogels and biological tissues.[27] For instance, strong, rapid adhesion 
between two hydrogels was achieved at room temperature by spreading 
a droplet of a NP solution on the surface of one gel and then bringing the 
other gel into contact with the droplet (Figure 1.5). Adsorption of NPs 
onto the polymer gel can connect polymer chains. In addition, pieces of 
calf liver can be glued together using a silica NP solution; furthermore, 
NP solution has been used as a hemostatic agent for bonding of medical 
devices,[54] since it can adhere to the wound without dislocating or 
blocking the tissues, unlike sutures or polymeric adhesives (Figure 1.6). 
This reduces trauma to soft tissues and avoids the inflammation induced 
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by or toxicity associated with polymeric cross-linkers. The NP adhesion 
strength can be increased by enlarging the NP surface area. For example, 
mesoporous silica NPs with a pore diameter of 6.45 nm have 35 J/m2 of 
adhesion energy, which is five times higher than that of non-porous silica 
NPs even at low concentrations.[55]  
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Figure 1.5. NP solution as an adhesive for hydrogels and biological 
tissues. a) Schematic illustration of gluing swollen polymer networks 
using NPs. b) Gluing of biological tissues with silica NPs. Two pieces of 
calf liver were glued together by spreading TM-50 nanosilica solution 
between them and then pressing them together by using the fingers. c) 
Normalized force-displacement curves for lap joints made of ribbons of 
cut calf liver glued together with TM-50 silica solution.
17 
 
Figure 1.6. Tissue repair in a full-thickness dorsal skin wound by 
SiO2NP nanobridging, suturing, or gluing with cyanoacrylate glue in a 
rat model. A drop of SiO2 NP solution was placed on the wound edge 
with a brush and the two wound edges were gently pressed into contact 
for about 1 min. The other wounds were closed with a non-resorbable 
suture (Ethicon 4/0) or 2-octyl cyanoacrylate (Dermabond).[54] 
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1.3 Application of NPs in minimally invasive procedures 
1.3.1 Minimally invasive procedures 
Incisions made in open surgery leave large wounds that are painful and 
require a long recovery time. The limited size of the incision during 
minimally invasive surgery reduces healing time as well as pain and risk 
of infection.[56] Minimally invasive approaches are used for endovascular 
aneurysm repair, embolization, and chemo-embolization in 
interventional radiology.[57] Remote ablation or treatment of target tissue 
can be achieved using an instrument generating gamma rays, laser light, 
or high-intensity ultrasound; these procedures are non-invasive since 
they do not involve injury to the skin or the introduction of foreign 
materials. Thermal ablation, photodynamic therapy, high-intensity 
focused ultrasound, and radiotherapy are also widely used non-invasive 
procedures.[58-61] 
Stem cell therapy is used to treat congenital diseases or to 
enhance regeneration of damaged tissues, and can replace conventional 
open surgeries. Providing therapeutic cells with an appropriate scaffold 
can contribute to the repair of structural damage in target tissue without 
pain and risks associated with surgery.[62-65] 
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A minimally invasive procedure typically involves the use of an 
endoscope, interventional medical modalities, and remote manipulation 
of instruments. Imaging modalities to visualize damaged tissues or 
lesions and appropriate agents to enhance the contrast between target and 
normal tissues are also required. Diagnostic pre-operative, interventional 
intra-operative, and post-operative imaging for tracking and follow-up is 
typically performed.[66] Since minimally invasive procedures are carried 
out in a limited space and with a small-sized incision, suitable medical 
materials including needle, stents, and markers are required. Moreover, 
internal soft tissue cannot be sutured or stapled in the limited space; only 
an adhesive on the incision can close the wound created during the 
procedure.[67,68] 
 
1.3.2 NPs in minimally invasive procedures 
Nanomaterials play important roles in imaging by delivering large 
imaging payloads, improving sensitivity, providing multiplexing 
capacity, and allowing modularity in design.[69] The magnetic, optical, 
acoustic, and X-ray-attenuating properties of NPs allows them to be 
combined with minimally invasive procedures (Figure 1.7).[70,71] 
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Various nanomaterials, including upconverting lanthanides, iron 
oxide, tantalum oxide, gold, and silica NPs, exhibit contrast 
enhancement capacity along with high sensitivity and 
biocompatibility.[72-74] The clinical application of NP-based contrast 
agents has recently increased following U.S. Food and Drug 
Administration approval. Minimally invasive procedures using NPs are 
being developed in various fields.[75] 
Biocompatibility and contrast enhancement can improve 
minimally invasive procedures by allowing accurate positioning and 
tracking of physiological movement. Moreover, conversion of light or 
sound energy into thermal energy using NPs can increase the efficacy of 
ablation therapies. Wound closure adhesives consisting of 
multifunctional NPs stimulate rapid recovery while minimizing 
inflammation and complications. The endoscope system combined with 
theranostic NPs allows the clinical application of fluorescence imaging 
and surface-enhanced Raman spectroscopy (SERS) for molecular 
imaging of gastrointestinal tract organs.  
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Figure 1.7. Nanomaterials for in vivo imaging. Schematic illustration of 
magnetic, optical, nuclear, acoustic, and adaptable nanomaterials for 
injection into living organisms.[69]  
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1.3.3 NPs for tracking therapeutic cells 
Cell-based therapies including immunotherapy and stem cell therapy 
(SCT) are novel therapeutic approaches in oncology. Limitations to SCT 
include cell death, contamination by undifferentiated cells, and cell 
delivery to non-targeted areas. Imaging can enhance the efficacy of SCT 
by enabling the proper delivery of cells and the monitoring of cell fate 
over the short and long terms.[76] 
Imaging is critical for determining the location and quantity of 
stem cells during transplantation as well as their redistribution during 
tissue repair.[77] Tracking implanted cells requires their labeling prior to 
administration. Cells can be genetically modified to express fluorescent 
protein so that they can be distinguished within tissue, but these cells can 
be tracked only by fluorescence imaging. Moreover, cellular activity is 
lost during transfection and exogenous protein expression. NP labeling 
provides other imaging modalities including magnetic resonance 
imaging (MRI), photoacoustic, and computed tomography (CT). MRI 
exhibits excellent resolution, soft tissue contrast, and high sensitivity; 
cell tracking by MRI was first reported nearly a decade ago and single-
cell imaging is now possible.[78-82] 
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Magnetosome-like NPs have been prepared by coating PEG-
phospholipid on ferromagnetic iron oxide nanocubes (FIONs). 
Pancreatic islet grafts and their rejection have been imaged using FIONs 
on a 1.5 T clinical MRI scanner.[83] Silica-coated gold nanorods can serve 
as a contrast agent for photoacoustic imaging and were used for 
quantitation of mesenchymal stem cells (MSCs) in rodent muscle tissue 
(Figure 1.8).[84] 
The positively charged NP surface is associated with a higher 
uptake ratio and efficient labeling. A simple method for rendering human 
MSCs sufficiently radiopaque via complexation of 40 nm citrate-
stabilized gold nanoparticles (AuNPs) with poly-L-lysine, and 
rhodamine B isothiocyanate is shown in Figure 1.9. AuNPs-labeled 
human MSCs can be clearly visualized in vitro and in vivo using a micro-
CT scanner.[85] Using a similar approach, human MSCs have been 
labeled with positively charged Prussian blue NPs and visualized by 
photoacoustic imaging (Figure 1.10).[86] 
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Figure 1.8. Iron oxide NPs for cell tracking. Cellular uptake of FIONs 
and MR images of single cells. (A) Prussian blue staining of MDA-MB-
231 breast cancer cells. (B) Trypsinized MDA-MB-231 cells; FIONs are 
visible as dark spots within the cells. (C) Transmission electron 
micrograph of FIONs trapped in an intracellular vesicle. (D) MR image 
of four labeled cells sandwiched between two Gelrite layers. (E) 
Fluorescence image of cells stained with calcein-AM. (F) Merged image 
of corresponding regions in panels (D) and (E).[84]  
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Figure 1.9. Positively charged AuNPs for labeling human MSCs. a) 
Schematic illustration and b) transmission electron micrograph of 40-nm 
core-diameter AuNP–poly-L-lysine–rhodamine B isothiocyanate 
complexes. c) In vivo micro-CT images of AuNP–poly-L-lysine-
rhodamine B isothiocyanate-labeled human MSCs after 30 min of 
transplantation into the striatum.[85]  
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Figure 1.10. Positively charged Prussian blue nanocomposite for cell 
tracking by photoacoustic imaging (a) Transmission electron micrograph 
of Prussian blue NPs. (b) Schematic illustration of PB−poly-L-lysine 
nanocomplex. Negatively charged, citrate-stabilized Prussian blue NPs 
are electrostatically complexed with positively charged poly-L-lysine. (c) 
B-mode ultrasound (gray scale) and photoacoustic (red) images of 
unlabeled (top) and labeled (bottom) human MSCs subcutaneously 
injected into nude mice.[86]  
27 
1.3.4 Enhanced remote ablation therapy using NPs 
Among non-invasive procedures, ablation therapy for tumor treatment 
[87] involves the delivery of incident energy through X-ray, laser, or 
focused ultrasound to damage tumor tissue.[88,89] Imaging and tracking 
of the tumor tissue is necessary to ensure effective ablation. Various 
contrast effects of NPs have been exploited to visualize tumors in an in 
vivo condition.[90-92] 
The therapeutic effect of ablation therapy can be enhanced by 
using energy-converting nanomaterials, which are delivered to tumor 
tissue prior to X-ray or near-infrared (NIR) laser irradiation. The 
selective ablation of target tissue prevents damaging normal tissues. In 
photothermal therapy, gold nanorods absorb NIR light and the resultant 
thermal energy can destroy tumors.[93] Various materials, including 
carbon nanotubes, FeS NPs, Cu2S NPs, graphene oxide, and nanoshell-
structured materials, can be used for photothermal therapy.[92,94]. 
Multifunctional NPs can enhance the efficiency of ablation 
therapy using high-intensity focused ultrasound (HIFU). Converting 
ultrasound energy into regional hyperthermia can induce tissue necrosis. 
However, the energy rapidly dissipates with increasing penetration depth, 
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and the thermal energy can damage tumor tissue only when the 
ultrasound beam is focused. Multifunctional NPs loaded with 
perfluorohexane can overcome these limitations by providing the 
spatiotemporal specificity to the targeting and by enhancing the 
conversion of ultrasound into the thermal energy.[95-98] Gold nanoshelled 
lipid perfluorocarbon magnetic nanocapsules, mesoporous silica-
encapsulating AuNPs, and magnetite-perfluorocarbon-loaded hybrid 
vesicle are the examples of theranostic NPs designed for image-guided 
HIFU treatment.[95-98] 
Magnetic NPs with ferromagnetic properties can be used for 
another type of ablation therapy. When alternating magnetic waves are 
applied to ferromagnetic NPs, the particles emit heat during relaxation. 
Since attenuation of magnetic fields in the body is negligible compared 
to that of visible or NIR light waves and does not result in the ionization 
of biological molecules, only tissue with magnetic NPs are ablated by 
magnetic thermal therapy or hyperthermia. Iron oxide and metal ferrite 
NPs are the main materials used for this treatment (Figure 1.11).[74,99] 
Reactive oxygen species (ROS) generated by photocatalytic 
reaction of NPs also enhance the efficiency of photodynamic therapy. 
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Increased ROS levels induce apoptosis of cancer cells, thereby 
decreasing tumor volume. Titanium dioxide and graphene oxides have 
photocatalytic properties in the absence of photodynamic drugs.[100,101] 
Materials with sonocatalytic effects generate ROS by absorbing sound 
energy.[102-104] The efficacy of radiation therapy using X- or gamma rays 
can be enhanced by NPs based on their contrast effect and scintillation 
properties. Several scintillating NPs are known to convert the high 
energy of X- or gamma rays into ultraviolet–visible light, enabling the 
combination of photodynamic and radiation therapies.[91,105,106]  NPs for 
remote ablation therapies can also be used for diagnostic purposes. These 
multifunctional theranostic agents allow minimally invasive procedures 
to be efficiently carried out.  
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Figure 1.11. Remote ablation therapy using magnetic NPs. (a) 
Radiofrequency (RF) ablation. (b) Magnetic thermal ablation with 
alternating magnetic field (AMF) (c) Schematic illustration of magnetic 
in vivo hyperthermia treatment to a mouse. (d) Nude mice xenografted 
with cancer cells (U87MG) before (upper row, dotted circle) and 18 days 
after (lower row) treatment. (e) Plot of tumor volume vs. time after 
treatment.[99]  
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1.3.5 NP-based wound closure materials 
Conventional polymeric tissue adhesives usually require complex in vivo 
control of polymerization or crosslinking. They may also be toxic, weak, 
or ineffective in an aqueous environment.[67] These disadvantages limit 
their usage for closing wounds inside the body. Nanotechnology has 
improved the properties and function of tissue adhesives for clinical 
use.[107] For example, NP solutions are used as adhesives and hemostatic 
materials to strongly bind the biological tissues together and stop the 
internal bleeding without the need for in situ polymerization. Surface 
modification of NPs can enhance their adsorption to tissues.[27,54] Silica 
NPs are highly effective for wound closure owing to their strong capacity 
for tissue adhesion; other metal oxide NPs including borate and bioactive 
glass, ceria and iron oxide NPs have also been investigated for their 
potential as adhesive materials.[108] Bioactive glass exhibits the strongest 
adhesion, whereas the iron oxide is comparable to silica and has been 
successfully used to stimulate the closure of a full-thickness skin incision. 
Iron oxide NPs can also serve as imaging probes to monitor the wound 
healing (Figures 1.12).[54] 
Tissue adhesives with antibacterial properties can be generated 
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through incorporation of antimicrobial NPs. Also hemostatic 
bioadhesives can be engineered by encapsulating the NPs into polymeric 
adhesives. Titanium dioxide and zinc oxide NPs have antimicrobial 
activities. By exploiting these properties along with their capacity for 
adsorption to hydrogel and soft tissue, NPs can serve as wound closure 
adhesives.[109] 
Increased ROS production at an injured site has deleterious 
effects such as cellular senescence, fibrotic scarring, and inflammation. 
The ROS-scavenging activity of ceria NPs can restrict the damage 
caused by oxidative stress. Immobilizing ultra-small ceria nanocrystals 
onto the surface of uniform MSNs yields ROS-scavenging 
nanocomposites that exhibit strong tissue adhesion and accelerate the 
wound healing (Figure 1.13).[110] Polymeric adhesives composited with 
upconverting NPs can promote the closure of wounds inside the body 
when stimulated by tissue-penetrating NIR light. A poly(allylamine)-
modified upconverting NP/hyaluronate−rose bengal conjugate complex 
was developed for photochemical bonding to deep tissue in response to 
NIR illumination (Figure 1.14).[111] The triggered-adhesion technology 
can be applied to the development of more sophisticated minimally 
invasive procedures.  
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Figure 1.12. Skin wound closure with iron oxide NP solution. At day 7 
post-injury, histological sections stained with hematoxylin-phloxin-
saffron showed signs of injury (thin line indicated by blue arrows). 
(Inset) Magnification of this area revealed a normal repair process and 





Figure 1.13. Schematic illustration of rapid cutaneous wound repair and 
tissue regeneration using MSN-ceria NPs as a ROS-scavenging tissue 
adhesive. At the initial stage, the ROS-scavenging tissue adhesive brings 
the edges of the wound together, restoring the tissue barrier function. 
Next, the adhesive alleviates oxidative stress at the injury site, providing 




Figure 1.14. Schematic illustration of photochemical tissue bonding of 
incised collagen matrix by NIR light illumination. The polyallylamine 
(PAAm)-modified upconversion NP/hyaluronate−rose bengal 
(UCNP/PAAm/HA-RB) conjugate complex was delivered to the dermis 
by transdermal incision.[111] 
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1.3.6 Combination of NPs and endoscopic system 
Endoscopic imaging is an invaluable diagnostic tool providing 
minimally invasive access to deep tissues inside the body. However, 
conventional white-light endoscopy provides only structural information. 
Various endoscopes have been developed for tumor detection and 
treatment. Combining the endoscope system and NPs allows early 
detection of lesions and enhances the efficacy of NP-based therapy. A 
non-contact, fiber optic-based Raman spectroscopy device has been 
constructed and shows unsurpassed sensitivity and multiplexing 
capabilities, detecting 326-fM concentrations of SERS NPs and 
unmixing 10 variations of colocalized SERS NPs (Figures 1.15).[112] A 
multifunctional endoscope-based system integrated with transparent 
bioelectronics has been combined with theranostic NPs to enable 





Figure 1.15. Raman endoscope design and setup with SERS NPs. (A) 
Schematic of Raman endoscope. (B) Photographs depicting the 
fabricated Raman endoscope used for clinical studies. (Lower) Enlarged 
digital photograph of the endoscope head (left); magnified view of the 
fiber bundle (center); and magnified view of the back end of the device 
(right). (C) Schematic illustration of the entire device setup.[112] 
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1.4 Dissertation overview 
Minimally invasive procedures require appropriate medical imaging 
modalities and materials. Improvement of minimally invasive 
procedures is propelled by the development of NPs for imaging, tissue 
adhesives and therapeutic agents. The efficiency of labeling cells with 
NP probes is increased by the strong adhesive capacity of NPs to cells. 
This dissertation focuses on the development of techniques for 
enhancing NP adhesion to cells and tissue, which is especially useful in 
the context of minimally invasive procedures. 
By coating thin silica layers on tantalum oxide NPs, I developed 
a biocompatible NP-based tissue adhesive with a high contrast effect for 
intraoperative imaging. An efficient and stable labeling method was 
developed for cell tracking by coating NPs on cells using thiol groups on 
the cell surface. 
Next chapter of this thesis (Chapter 2) describes the synthesis of 
tantalum oxide/silica core/shell NPs (TSNs) that exhibit comparable 
tissue adhesive properties to those of clinical adhesives being used in 
minimally invasive procedures. Silica coating and removal of excess 
surfactants increased the adhesion strength of TSNs. These NPs also 
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provided a strong contrast effect in real-time imaging modalities 
including X-ray fluoroscopy, CT, ultrasonography, and fluorescence 
imaging. Furthermore, TSNs were less cytotoxic and caused less 
inflammation than the cyanoacrylate adhesives. The excellent 
biocompatibility, immediate hemostatic and strong contrast effects of 
TSNs as a tissue adhesive and an injectable fiducial marker were 
demonstrated in a real-time image-guided procedure. 
Chapter 3 presents a general method of NP conjugation to the cell 
surface. Active thiol groups were introduced through mild reduction of 
disulfide bonds of proteins on the cell surface. MSNs were successfully 
attached to the cell surface via these active thiol groups. To conjugate 
NPs with active thiol moieties, the MSN surface was modified with a 
maleimide moiety. This conjugation method is more rapid than genetic 
labeling or cellular uptake of NPs. Being stable in a complex biological 
environment, the attached NPs allowed the visualization of cell 
morphology with fluorescence signals by intra-vital microscopic 
imaging. MSNs loaded with the immunosuppressant dexamethasone 
were attached to the cell surface and efficiently delivered the drug, 
enhancing cellular activities and overcoming of immune rejection in 
mice. Thus, the surface modification of NPs for adhesion to and labeling 
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Chapter 2. Multifunctional nanoparticles as a 




Tissue adhesives have various advantages over sutures and staples, 
including a simpler implementation procedure, more immediate sealing, 
less pain to patients, lower infection rates, and less trauma on operated 
tissues.[1-4] Hence, their clinical demands have grown significantly, and 
consequently, a number of tissue adhesives based on proteins and 
synthetic polymers including fibrin, gelatin, polyurethanes, and 
polyethylene glycol have been developed to accommodate various 
surgical situations.[5-10] The convenience of tissue adhesives is 
particularly noticeable in minimally invasive procedures and image-
guided surgeries because they are very effective for treating a confined 
region of interest that is inaccessible with other wound closure methods, 
which can greatly reduce postoperative complications. Since minimally 
invasive procedures are typically guided by real-time imaging modalities, 
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such as X-ray fluoroscopy, computed tomography (CT), ultrasonography, 
and fluorescence imaging, it is useful that the applied tissue adhesives 
are visible with such imaging modalities for accurate and safe 
applications.[11-13] Moreover, radiotherapy or minimally invasive 
procedures to soft organs can also be aided by the tissue adhesives with 
imaging contrast effects for efficient recognition and follow-up of the 
target areas along the physiological movement of the organ.[14,15]  
Nanoparticles have been incorporated with tissue adhesives or 
hydrogels to enhance their mechanical properties, adhesive strength, and 
electrical conductivity and to provide unique functions such as 
antibacterial effects.[4,16-18] Recently, it was reported that the nanoparticle 
solution itself can act as an adhesive for hydrogels and biological tissues. 
[19] Owing to its large surface area and the high adsorption energy 
between biological tissues and the nanoparticle surface, the adhesive 
property of nanoparticles is sufficient for various applications, such as 
hemostasis, wound closure, and scaffold-attachments.[20] On the other 
hand, nanoparticles have also been employed as biomedical imaging 
probes owing to their unique physical properties and capability of 
conjugating functional moieties via surface modification.[21-29] They 
have been used with various molecular imaging modalities for the 
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sensitive diagnosis of lesions.[30-37] Based on these two different medical 
applications of nanoparticles, they may be a promising candidate for 
multimodal image-guided procedures.[38-40] 
Herein, we design core-shell structured tantalum oxide-silica 
nanoparticles as tissue adhesives in image-guided surgery (Figure 2.1a). 
We employ silica (SiO2) as the shell material to endow the nanoparticles 
with a tissue adhesive property, because its surface offers high adhesive 
strength to hydrogels or tissues.[19] Radiopaque tantalum oxide (TaOx) is 
selected as the core material to provide contrast enhancement on X-ray 
fluoroscopy and CT. TaOx nanoparticles combined with various organic 
and inorganic moieties have been applied to multimodal imaging and/or 
theranostics.[41-48] In the current study, the high density of the TaOx core 
and the facile modification of the SiO2 surface allow for ultrasound (US) 
and fluorescence imaging. As designed, the TaOx/SiO2 core/shell 
nanoparticle (TSN) glue is clearly visualized by real-time imaging 
modalities, which facilitates image-guided, less-invasive procedures 
using this material, and exhibits adhesive property similar to that of a 
mixture of cyanoacrylate and Lipiodol used in clinical practice. 
Cyanoacrylate adhesive including Histoacryl (B. Braun, Melsungen, 
Germany), a frequently used tissue adhesive in human, has to be mixed 
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with radiopaque, iodized oil (Lipiodol; Andre Guerbe, Aulnay-sous-Bios, 
France) – the most commonly used form is a 1:3 (v/v) mixture of 
cyanoacrylate and Lipiodol (CA-Lp) – to be administered under the 
guidance of fluoroscopy. In the present study, tissue adhesive properties 
of the TSN is comparable with those of CA-Lp (Figure 2.1b). Moreover, 
TSNs are highly biocompatible, as evidenced by dramatically reduced 
cytotoxicity and inflammation reaction compared to the clinically used 
CA-Lp. We also demonstrate that TSNs can work as tissue adhesives 
with the assistance of multimodal imaging modalities in a liver puncture 
model to stop internal bleeding. Because of their adhesive property and 
multimodal imaging capability, TSNs are used as an injectable 





Figure 2.1. Tantalum oxide/silica core/shell nanoparticles (TSNs) as an 
adhesive for multimodal image-guided procedures. a, Schematic 
illustration of a multifunctional TSN with a radiopaque core for X-ray 
imaging, conjugated fluorescent dye for fluorescent imaging, a dense 
core material with a high sound-scattering effect for ultrasound imaging, 
and a silica surface for adhesive property. b, Representative images 
demonstrating multifunctionality of TSNs.  
58 
2.2 Experimental Section 
 
2.2.1 Preparation of TSNs 
The TSNs were synthesized by the aqueous sol-gel reaction confined in 
reverse-micelles based on the previous report.[41] Igepal CO-520 (46 g, 
Sigma-Aldrich), ethanol (5 ml, Samchun, 99.9%), aqueous NaOH 
solution (5 ml, 150 mM, Samchun) were mixed with cyclohexane (800 
ml, Samchun, 99.5%) to form a microemulsion under vigorous stirring. 
To the resulting transparent solution, tantalum ethoxide (1 ml, 3.85 mmol, 
Strem, 99.8%) was injected at room temperature, and stirred for 30 min. 
Subsequently, 28% ammonium hydroxide solution (5 ml, Samchun) and 
tetraethyl orthosilicate (TEOS, 1 ml, 4.47 mmol, Acros, 98%) were 
successively added. The mixture was stirred at room temperature for 12 
h. After the reaction, the solvents were removed by evaporation at 60 oC, 
until the solution became white and viscous. The synthesized 
nanoparticles were separated by centrifugation, and dispersed in ethanol. 
In order to remove the adsorbed surfactants, 5 ml of hydrochloric acid 
(Daejung, 35%) was added, and the nanoparticles were centrifuged and 
subsequently washed with ethanol twice. The solution was neutralized 
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by washing twice each with 20 ml of phosphate buffer (pH = 8.0, 0.1 M) 
and distilled water. Finally, the solution was concentrated up to 40 wt% 
and loaded into a 1-ml syringe. 
 
2.2.2 Rhodamine conjugation and surface modification of the TSNs  
The conjugation of TSNs was performed by mixing acid-treated 
nanoparticles with dye-conjugated silane. Tetramethylrhodamine 
isothiocyanate (0.44 mg, Sigma-Aldrich, mixed isomers) and (3-
aminopropyl)trimethoxysilane (0.18 mg, Sigma-Aldrich, 97%) were 
dissolved in 0.5 ml of dimethylformamide (Samchun, 99.5%), and the 
solution was shaken gently for 30 min. The resulting dye solution was 
added to the nanoparticle solution dispersed in the phosphate buffer (pH 
= 8.0), and kept being shaken over 8 hours. The unreacted dye molecules 
were removed by several centrifugations, and the resulting nanoparticles 
were dispersed in distilled water.  
 
2.2.3 Preparation of CA-Lp and SiO2 NPs 
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CA-Lp was prepared by mixing Histoacryl® (B.Braun Surgical, 
Germany) and Lipiodol Ultra-Fluid® (Guerbet, France) with a 
volumetric ratio of 1:3, to have a comparable fluoroscope contrast effect, 
with the iodine concentration of 360 mgI ml-1. CA-Lp was prepared 
right before the experiments to avoid the loss of the adhesive properties. 
To make a comparison with the reported nano-bridging SiO2 NPs, 
Ludox® TM-50 (50 wt% of silica) was purchased from Sigma-Aldrich 
and used without any treatment.[19,20]  
 
2.2.4 Characterization of TSNs and SiO2 NPs 
TSNs and SiO2 NPs were analyzed using a transmission electron 
microscope (TEM, 200 kV, JEOL-2100, JEOL Ltd., Japan). Fourier 
transform infrared (FT-IR) spectra were obtained with a JASCO FT/IR-
200 (Jasco Inc., Japan). Hydrodynamic diameters and ζ-potentials of the 
nanoparticles dispersed in water were analyzed with a size analyzer 
(Nanozs, Malvern, Germany). The absorption and emission spectra of 
the rhodamine-conjugated nanoparticles and free dye were measured 
with a SpectroV-550 (Jasco inc., Japan) and a FP-5500 (Jasco Inc., 
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Japan). Nitrogen adsorption/desorption isotherm was measured by a 
3FLEX surface characterization analyzer (Micromeritics, USA).  
 
2.2.5 Evaluation of contrast effect 
Each type of the adhesive (TSNs, SiO2 NPs and CA-Lp) was loaded into 
a 2-ml tube. The contrast effect on fluoroscopy was measured with 
images acquired by an Allura Xper FD20 (Philips, Netherlands, at 80 kV 
of tube voltage). The SNR was calculated as SNR = S / N, where S is the 
mean attenuation of each material and N is the standard deviation of 
background attenuation. Dose-dependent contrast enhancement was 
examined by comparing the TSNs with SiO2 NPs (Ludox® TM-50) and 
a contrast agent (iopamidol, Pamiray®, Dongkook pharmaceutical Co., 
Korea) which were prepared with the same mass concentration. The 
solutions containing the nanoparticles or the contrast agent was diluted 
sequentially and dispersed in 1 wt% agarose gel and loaded to 200 μl 
microtubes. Both fluoroscopy and CT were used to analyze these series 
of tubes, and the obtained images were evaluated with the OsiriX 
software (version 4.0; 32 bit; OsiriX foundation Geneva). The clinical 
CT scanner (Brilliance 64, Philips Medical System, USA) was operated 
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at 140 kVp and 150 mA. To compare the US contrast effect of the TSNs 
with other glues, 50 μl of each glue was injected to fresh calf liver using 
an 18-gauge needle while withdrawing a syringe. Afterwards, B-mode 
US images were obtained with an Accuvix V10 (Samsung Medison co., 
Ltd, Korea). The mean intensity and standard deviation of each region-
of-interest were calculated with the ImageJ software (version 1.48v, 
NIH). To evaluate the contrast effect in serial dilution, the SiO2 NPs and 
TSNs were diluted using 1 wt% agarose, and 200 μl of each solution 
were cured in a 96-well plate. The plate was immersed in a water bath 
and the backscattered amplitudes were measured with the same method 
used in the calf specimens. 
 
2.2.6 Adhesion strength test 
Fresh calf livers were cut into several pieces of ribbon shape (45 mm × 
10 mm × 4 mm each) with a scalpel and an autopsy blade. Two pieces of 
the calf liver ribbons were adhered by applying ~15 μl of each glue. The 
ribbon pieces were overlapped by 10 mm, and the overlapped portion 
was gently pressed by a finger for 10 seconds. To quantify the adhesive 
strength of the lap joints attached by the glues, lap-shear tests were 
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performed by using an Instron-5543 electromechanical system (Instron, 
USA) controlled by the Bluehill software (Ver. 3). The lab joints were 
placed in a 50 N load cell and the test was performed at a speed of 30 
mm min-1. Each displacement-force curves were calibrated to the points 
after slipping, not to be influenced by weights of the lower ribbon of liver. 
 
2.2.7 Electron microscopic imaging of liver tissue 
Electron microscope samples were prepared by fixation and dehydration 
of the calf liver tissues attached with TSNs. The adhered tissues were 
fixed with 2.5% of glutaraldehyde and 2% of paraformaldehyde in 0.1 
M of sodium cacodylate buffer (pH 7.4), which was then rinsed with 
cacodylate buffer. Additional fixation was proceeded with 1% osmium 
tetraoxide solution in cacodylate buffer. After washing the residual 
fixation reagent with distilled water three times, they were stained 
overnight with 2% uranyl acetate solution. The dehydration was 
proceeded gradually with ethanol, by incubating them for 10 min in 30%, 
50%, 70%, 80%, 90% ethanol, and finally absolute ethanol three times 
to eliminate water in the tissues. For scanning electron microscope (SEM) 
sample, the tissues were dried with critical point drier (EM CPD 300, 
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Lieca, Austria) and coated with Pt by sputter coater (EM ACE200, Leica, 
Austria). For TEM samples, Spurr’s resin was used in order to 
ultramicrotome sectioning. Further solvent exchange and infiltration of 
the resin were proceeded by incubating the dehydrated tissues in 
propylene oxide twice for 10 min, in 50% Spurr’s resin with propylene 
oxide for 2 h, and finally in Spurr’s resin overnight. The tissues were 
embedded in fresh Spurr’s resin at 60 oC for 24 h. The embedded 
samples were cut with ultramicrotome (EM UC7, Leica, Germany). 
SEM images were obtained with JSM-6701F (JEOL Ltd., Japan) and 
energy dispersive X-ray spectrometer (EDS) spectra and element 
mapping were performed using the attached INCA Energy (Oxford 
Instruments Analytical Ltd., UK). TEM images were obtained with 
JEM1010 (JEOL Ltd. Japan).  
 
2.2.8 Cell culture 
Hela cells from Korean Cell Line Bank (KCLB) were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco). The medium 
was supplemented with 10% fetal bovine serum (FBS, Gibco BRL), 100 
μg mL-1 streptomycin, and 100 IU penicillin (Gibco BRL). Cells were 
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grown as monolayer cultures in a T75-flask and sub-cultured three times 
in one week at 37 °C in atmosphere containing 5% CO2 and 100% 
relative humidity.  
 
2.2.9 Morphological analysis  
A 20-μl drop of TSNs or CA-Lp was placed on the middle of coverglass-
bottom dish. A Cell suspension in a logarithmic growth phase was added 
to the dish. Following 24 h of cell seeding onto the dish, bright field 
images were taken by an inverted confocal microscope (LSM 780, Carl-
Zeiss, Germany). 
 
2.2.10 Viability assay 
For the in vitro cytotoxicity assay, cells in a logarithmic growth phase 
were detached and plated (400 μL per well) in 24-well flat-bottom 
microplates at a density of 40,000 cells per well, which were then left for 
24 h at 37 °C to resume exponential growth. After 24 h of recovery, the 
cellular media were exchanged with the media containing TSNs with 
various concentrations. As CA polymerizes and hardens with water 
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contact, it is hard to be diluted in PBS or cellular media. Alternatively, 
we put a drop of CA-Lp gel in the well, letting some molecules or 
materials be dissolved naturally and affect the cells. After the removal of 
the media in wells, different volume of the CA-Lp (100, 200, 400, and 
800 μl) and different concentrations of TSNs were introduced to each 
culture well, and incubated with 1 ml of cellular media. Following 24 h 
exposure of the glues to the cells under the same culturing condition, cell 
viability was assessed by MTT (3-[4,5-dimethylthialzol-2-yl]-2,5-
diphenyltetrazolium bromide, Sigma) assay. The assay was performed in 
quadruplicate in the following manner. The cells were incubated in 
media with 1 mg ml-1 of MTT solution for 2 h. Then the MTT solution 
was removed and the precipitated violet crystals were dissolved in 1 ml 
dimethylsulfoxide (DMSO). The absorbance of the solution was 
measured at 490 nm with microplate reader (Victor X4, Perkin-Elmer, 
USA).  
  
2.2.11 Preparation of SiO2 NPs and TaOx NPs for hemolysis test 
The 105 nm-sized SiO2 NPs were synthesized with Stober process, and 
22 nm-sized SiO2 NPs were prepared with the same microemulsion 
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method used in preparation of TSN, except that the precursor was 
changed to tetramethyl orthosilicate. The 120 nm-sized TaOx NPs were 
synthesized by aqueous sol-gel reaction of Ta(OEt)5 in 90% ethanol 
aqueous solution. 
 
2.2.12 Hemolysis assay 
Rabbit blood was collected freshly and stabilized with sodium-heparin. 
To remove plasma from the whole blood, 4 ml of whole blood was 
diluted with 12 ml of PBS and centrifuged at 10000 rpm for 5 min. The 
supernatant including plasma was removed carefully, and the cells were 
suspended with additional 12 ml of PBS. Red blood cells (RBC) were 
isolated by several washing process with 12 ml of PBS and the final 
solution was diluted with 40 ml of PBS. The nanoparticle solution was 
diluted with PBS to the various concentrations, and prepared in triplicate. 
To assess the hemolysis effect, 0.8 ml of the nanoparticle solution and 
0.2 ml of the diluted RBC suspension were mixed to reach the final 
particle concentrations of 100, 200, 500, 1000 μg ml-1. For negative and 
positive controls, PBS and distilled water were mixed with the same 
amount of RBC, respectively. The mixtures were incubated at room 
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temperature for 24 h, followed by a centrifugation at 10000 rpm for 5 
min. Each 200 μl of the supernatant of the mixture were conveyed to a 
96-well plate and its absorbance was measured at 490 nm with a 
microplate reader. The percentage of the hemolysis of RBCs was 
calculated by following formula: percent of hemolysis = ((sample 
absorbance - negative control absorbance)/(positive control absorbance 
- negative control absorbance))×100. 
 
2.2.13 Degradation experiments of TSN in simulated body fluid 
The simulated body fluid (SBF) was prepared as previous report.[49] Each 
500 ml of SBF was prepared in polyethylene bottle TSN was immersed 
with concentration of 200 mg L-1, and 400 mg L-1. About 10 ml of the 
sample solutions were extracted each time with centrifugal filter unit 
(Amicon®, 3kDa). The concentration of free tantalum were determined 
using inductively coupled plasma mass spectrometry (Elan 6100, 
PerkinElmer) of National center for inter-university research facilities, 
Seoul National University. 
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2.2.14 Migration experiments for various fiducial markers 
Five different markers such as a contrast agent (Lipiodol), adhesive 
mixture (CA-Lp), coil, gold rod, and TSNs were implanted or injected 
into calf liver and lung specimen. The calf liver and lung were prepared 
freshly by cutting into proper sized cuboid and put into airtight 
containers. Fifteen needles were attached uprightly in order to hold the 
specimens in the containers. Those were imaged with a CT scanner after 
1, 3, 5 and 10 hours of shaking. The migration distances were measured 
according to the method of a previous report.[50] 
 
2.2.15 Animal study 
 All procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the Clinical Research Institute of Seoul National 
University Hospital, and all experimental procedures were performed 
according to the IACUC guidelines. 
 
2.2.16 Liver puncture model in SD rat 
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Ten male Sprague-Dawley (SD) rats, at the age of 12 weeks, initially 
weighing about 400 g, were randomly divided by two groups (i.e. five 
rats per group) and each group was treated by TSNs and CA-Lp. The rats 
were anesthetized by intramuscular injection of a mixture of zolazepam 
(5 mg kg-1, Zoletil®, Virbac, Carros, France) and xylazine (10 mg kg-1, 
Rompun®, Bayer-Schering Pharma, Berlin, Germany). To apply the 
glues to the rat liver and to evaluate their hemostatic effect, the left lobe 
of the liver of was exposed by a median abdominal incision. After 
creating a liver stab wound, 18-gauge in diameter (1.27 mm) and 1.5 cm 
in length, the needle track was closed with the TSNs or CA-Lp mixture 
preloaded within a syringe. 0.03 mL of the adhesives was slowly injected 
during the withdrawal of the needle. In order to measure the amount of 
bleeding, hydrophobic films (Parafilm) were put on each lower and 
upper side of the liver and filter paper was put right onto the wound area. 
After bleeding stopped, the amount of the absorbed blood was calculated 
by measuring the change of the weight of the filter papers. 
CT and fluoroscopy images were acquired after the abdominal 
closure. Fluoroscopic images were obtained with exposure of X-ray at 
80 kV for 3 ms. CT imaging parameters of the SD rats were as followed: 
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thickness, 0.6 mm; pitch, 0.648; 120 kVp, 300 mA; field of view, 
127×127; gantry rotation time, 0.75 s; table speed, 16.7 mm s-1.  
 
2.2.17 Image-guided procedure in a rabbit liver puncture model 
Demonstration of image-guided procedures was conducted with a male 
New Zealand White rabbit weighing 3.5 kg, with the same method in SD 
rats, except the abdominal incision and exposure of the liver. An 18-
gauge stainless steel needle was used to make an intrahepatic track under 
the guidance of US and fluoroscopy, and 0.05 mL of the adhesives was 
slowly injected during the withdrawal of the needle. During the image-
guided procedure, the operation video and fluoroscopy video were 
recorded simultaneously. The fluoroscopic images were acquired with 
exposure of X-ray at 60 kV for 1 ms.  
 
2.2.18 Percutaneous anatomical marking in rats 
The rats were euthanized by the same method used in the liver puncture 
model. Regarding the clinical contexts where fiducial marking for 
subsequent image-guided surgery or radiotherapy is frequently used (i.e. 
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musculoskeletal tumors and lung tumors), experiments were conducted 
for the leg muscles and syngeneic lung tumor. The muscle and lung 
marking studies were conducted with two male SD rats (12-week-old, 
400g) and two male F344 rats (12-week-old, 300g), respectively. 
Regarding the muscular injection study, 0.02 mL of TSNs was gently 
implanted into the thigh and calf muscles of male SD rats though a 22-
gauge needle. The fiducial markers were observed on micro-CT, real-
time fluoroscopy, and fluorescent imaging (IVIS 100, Perkin Elmer). 
During the fluoroscopic study, the TSN-implanted leg was manually 
flexed and extended to address whether the fiducial marker was changed 
in its shape and/or position. To obtain fluorescent signals from the deep 
muscles, the legs were skinned before fluorescent imaging. For creating 
a syngeneic lung cancer model, a 0.5×0.5×0.5 cm sized tumor chip 
(13762-MAT-B-III cell-line [CRL-1666, ATCC, Manassas, VA, USA]) 
was injected into the tail vein of male F344 rats. After 10 days, the rats 
underwent a CT study to identify lung embolization and growth of the 
tumor chip. A 25-gauge needle was precisely advanced to the lung tumor 
under CT imaging guidance, and then 0.02 mL of pre-loaded TSNs was 
slowly injected into the target. The markers were also observed on CT, 
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real-time fluoroscopy, and fluorescent imaging that obtained after 
thoracostomy. 
 
2.2.19 Histological analysis 
The rats were euthanized in a CO2 chamber, and then the liver was 
excised and fixed in 10% neutral buffered formalin (10% NBF) for one 
week. For hematoxylin and eosin (H&E) staining, formalin fixed tissues 
from each specimen were embedded into paraffin and sectioned into 4 
μm thickness. Standard H&E staining was performed to evaluate 
morphological features of each specimen regarding inflammatory 
reactions and fibrosis as time passes. The pathologic slides were also 
analyzed with CD68 immunohistochemistry (CD68 antibody, sc-59103, 
Santa Cruz Biotechnology) to address macrophage recruitment after 
liver puncture. Afterwards, all samples were digitalized with optical 
magnification (×200) to conduct further analyses. The slides were 
carefully reviewed by an experienced pathologist who was blinded to the 
kinds of adhesives. 
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2.2.20 In vivo toxicity evaluation of TSN 
To assess the in vivo toxicity of the TSNs, serum chemistry and 
biodistribution of the NPs were evaluated. 30 μL of the TSNs solution 
and CA-Lp mixture was applied to SD rats. Since we are interested in 
two different regions of application, rats were divided into two groups; 
one is for the liver and the other is for muscle. Rats were sacrificed after 
3, 7, 28 and 42 days from the nanoparticle application, and the 
reticuloendothelial system (liver, spleen and kidney), blood, heart, 
muscle and lung were harvested. In the target organ (liver and muscle), 
two different regions within the same organ were collected. The tissues 
were firstly digested with nitric acid, and hydrofluoric acid was added to 
dissolve TSNs. Ta concentration was determined from inductively 
coupled plasma mass spectrometer (ICP-MS, NexION300, Perkin Elmer, 
USA). By collecting 2-ml blood samples from the tail vein of the SD rats, 
serum biochemistry was examined from the analysis for inflammation 
(CRP), liver function (ALP, AST, ALT), and kidney function (BUN, 




2.2.21 Statistical analysis  
Data are shown as mean ± s.d, except Supplementary Figure 5b and 7b. 
Statistical analyses of intergroup comparisons were performed using a 
two-sided unpaired Student’s t-test and one-way ANOVA tests were used 
to results having multiple groups. P < 0.05 was considered significant. 
The investigators were not blinded to group allocations during the 
experiments and analyses except for the histological analysis, and no 
randomization method was used. Sizes of sample were determined to 
empirically for sufficient statistical power. 
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2.3 Result and Discussion 
 
2.3.1 Synthesis and characterization of TaOx/SiO2 core/shell NPs 
TSNs were synthesized by the sol-gel reaction of tantalum(V) ethoxide 
in nanometer-sized microemulsion.[41] After TaOx nanoparticles were 
generated, the SiO2 shell was grown on the TaOx core by sol-gel reaction 
of tetraethoxysilane (TEOS). Transmission electron microscopy (TEM) 
images show uniform nanoparticles of an overall size of 8.5 ± 0.8 nm 
with a SiO2 shell thickness of 1.3 ± 0.2 nm (Figure 2.2d). After the 
nanoparticles were purified by centrifugation, they were treated with acid 
to remove any residual adsorbed surfactants that may interfere with the 
interactions between the nanoparticle surface and biological tissues, 
leading to the loss of the adhesive property. Removal of the surfactants 
was confirmed with Fourier transform infrared spectroscopy by the 
disappearance of peaks related to Igepal CO-520 (Figure 2.3). Without 
the SiO2 shell, the reactive TaOx surface causes a severe aggregation of 
tantalum oxide nanoparticles after the removal of surfactants (Figure 
2.2a), generating micrometer-sized agglomerates (Figure 2.4a). 
However, the SiO2 shell successfully protects TSNs from irreversible 
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agglomeration, resulting in the number-average hydrodynamic diameter 
of 20.4 nm (Figure 2.4b). It is crucial that the TSNs should be well 
dispersed as nanoparticle form because the adhesive property of the 
nanoparticles is affected by surface adsorption with biological tissue, 
which will be discussed below. In order to utilize TSNs for optical image-
guided surgery, fluorescent TSNs were prepared by covalent attachment 
of tetramethylrhodamine isothiocyanate (TRITC) onto the TSN surface. 
Photoluminescence of the TRITC-conjugated TSNs reveals a typical 





Figure 2.2. (a) TEM image of TaOx nanoparticles without SiO2 shell, 
which is agglomerated to micron-size. (b) TEM image of TSNs after the 
acid treatment, which are dispersed well. (c) high magnified TEM 






Figure 2.3. FT-IR spectra of surfactant, Igepal® CO-520 (black line), 
TSNs before the acid treatment which the surfactants are adsorbed (red 





Figure 2.4. (a) Volume distributions of hydrodynamic diameter of SiO2 
NPs, and TSNs. (b) Number distribution. (c) ζ-potential intensity 
distributions. (d) Absorption and emission spectra of the 






2.3.2 Tissue adhesive property and hemostatic capability 
In order to evaluate the suitability of the TSNs for image-guided 
procedures, their adhesive property was examined with internal tissues 
containing biological fluids. Liver is an appropriate substrate because it 
contains abundant biological fluid and blood vessels which have to be 
sealed inside and it has rather uniform structures among the internal 
organs. The tissue adhesive property of TSNs was evaluated using a lap 
joint shear test of liver ribbons. Two liver ribbons were adhered together 
by gently pressing with a fingertip after spreading 15 µl of the glue 
solutions (TSNs, SiO2 nanoparticles (SiO2 NPs), TaOx NPs, 
cyanoacrylate-Lipiodol mixture (CA-Lp), and TSNs coated with Igepal 
CO-520). Here, CA-Lp was used as a positive control group because it 
is a U.S. Food and Drug Administration-approved tissue adhesive form 
with a contrast effect and one of the most commonly used glue in image-
guided procedures for human. When the upper ribbon was lifted with 
forceps, it held the lower ribbon without slipping (Figure 2.5a). Force-
displacement curves were obtained using a universal test machine (UTM) 
as shown in Figure 2.6. In order to account for the large deviation of 
failure forces due to tissue heterogeneity, nine samples were measured 
for each type of glue (Figure 2.6 and Figure 2.7). The adhesive 
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strengths of all applied adhesives exceeded the intrinsic adhesion 
strength of biological tissues.  
TSNs exhibit an adhesion strength comparable to that of CA-Lp 
(1:3) mixture that has enough contrast effect to be visualized in X-ray 
fluoroscopy (Figure 2.16c and Figure 2.16d). SiO2 NP solution also 
shows similar strength with that of CA-Lp and TSNs. Although the TSNs 
show much lower adhesion strength than that of commercial CA, the CA 
is not detectable in X-ray imaging modalities, and unable to be used by 
itself in image-guided procedures. To determine the optimal 
concentration of TSN for adhesive properties, the adhesive strengths 
were measured with various TSN concentrations. Because the adhesive 
force increases with increasing nanoparticle concentration (Figure 2.8), 
the highest 40 wt% TSN solution was used for hemostasis or markers. 
The force-displacement curves of TSNs (Supplementary Fig. 5a) show a 
similar pattern to that of SiO2 NPs, indicating that the adhesion 
characteristics of TSNs originate from nanoparticle adsorption onto the 
biological tissue surface and corresponding energy dissipation from the 
hydrogel-like soft tissues, as previously proposed.[19]  
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Gluing biological tissues with nanoparticles mainly depends on 
the ability of nanoparticles to adsorb onto tissues, which involves the 
interaction between the nanoparticle surface and biological molecules on 
tissues.[19,51] To investigate the adhesive mechanism of TSNs, we 
prepared various types of TSNs that are surface-functionalized with 
primary amine, carboxylate, and polyethylene oxide group (Table 2.1, 
Figure 2.9). All of these surface grafted TSNs exhibit no adhesive 
property (Figure 2.10 and Figure 2.11). On the other hand, TSNs 
covered with Igepal CO-520 show fourfold reduced adhesive property 
than that of bare TSNs that are obtained by the complete removal of 
Igepal CO-520 by the acid treatment (Figure 2.11). Meanwhile, 
agglomeration of TaOx NPs leads to the decrease of adhesion strength by 
half compared with TSNs (Figure 2.4). These results clearly demonstrate 
that the silica surface is mainly responsible for the adhesive property of 
TSNs. Furthermore, silica coating imparts colloidal stability of TSNs. 
Adsorption of TSNs was investigated using scanning electron 
microscopy (SEM) and TEM. SEM and TEM images of the liver samples 
show localization of TSNs near hepatocytes and leaked subcellular 
vesicles from the damaged cells by the adsorption of TSNs near lipid 
layer (Figure 2.12 and Figure 2.13). Moreover, entangling and 
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adsorption interactions between fibrin fibers and TSNs confirm that the 
adsorption and spontaneous network formation of TSNs on biological 
tissues enables the adhesion of cut liver tissues (Figure 2.12h).  
After confirming their adhesive property, TSNs were applied to 
hemostasis in a liver puncture model. Since it is difficult to suture a 
highly vascularized liver wound, either tissue adhesives or sealants are 
necessary for the warranted closure of hepatic wounds. Puncture injuries 
were prepared by making a track with a sterile 18-guage needle in the 
livers of Sprague-Dawley (SD) rats. Subsequently, TSNs, SiO2 NPs, or 
CA-Lp mixture was applied to each track as a hemostatic agent, or direct 
pressure was put onto the stab wound as a control. Because it is almost 
impossible to impose pressure in a minimally invasive procedure, no 
pressure was applied at the sites where the adhesives were treated. As 
shown in Figure 2.15a, both TSNs and CA-Lp successfully stopped 
bleeding immediately after their application. However, severe blood loss 
occurred in the control without any adhesives, even though direct 
pressure was exerted. The amount of bleeding was measured by the 
weight difference of a filter paper before and after absorbing the blood 
(Figure 2.14). A significant decrease in the amount of blood was 
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observed when TSNs, SiO2 NPs, or CA-Lp was applied, and their 






Figure 2.5. (a) Photographs showing the lap joint preparation procedure 
for analyzing adhesive strength of various glues on biological tissues of 
two calf liver ribbons: applying the adhesive, attaching by overlapping 
the ribbons at the region where the adhesive was applied, gently pressing 
the ribbon for 30 sec, and lifting up and moving the joint to be analyzed. 
(b) Photographs showing the lap joint shear test (i) lifting the lower 







Figure 2.6. Normalized force-displacements curves of the lab joints 
made of ribbons cut from the calf liver and glued with intrinsic adhesive 
property of biological tissues (Control), CA-Lp, SiO2 NPs, surfactant-
free TaOx/SiO2 core/shell nanoparticles (TSN), and TaOx NPs without 






Figure 2.7. (a) Box plot for the failure forces of each adhesive. Each 
failure force is denoted with diamond, bars represent maximum and 
minimum values, and boxes with line are represented the interquartile 
range with median. (b) Bar plot of mean shear stress. Error bars show the 
standard deviation. p value were calculated by student’s t-test. 










Table 2.1. Zeta-potentials and hydrodynamic diameters of TSNs with 











Figure 2.10. Normalized force-displacements curves of PEG-TSNs, 
Amine-TSNs, Carboxyl-TSNs, surfactant-adsorbed TSNs 
(TSN+Surfactant; without acid treatment). The failure force value is 






Figure 2.11. (a) Box plot for the failure force of each adhesive. Each 
failure force is denoted with diamond. Bars represent maximum and 
minimum values. Boxes with line represent the interquartile range with 







Figure 2.12. (a) Scanning electron microscope(SEM) image of the side 
of liver where TSNs applied. (b) SEM image showing nanoparticles 
coating the leaked vesicle by adsorption. (c) Highly magnified image 
showing the adsorbed nanoparticles. (d) Carbon and (e) silicon elemental 
mapping of the image (a) by energy-dispersive X-ray spectroscopy 
(EDS) showing wide adsorption of TSN onto the liver section. (f), EDS 
spectra of image (a) showing the tantalum and silicon peaks. (g), SEM 
image where fibrin fibers are networked with TSN. The blue arrows 
point the locations of TSN agglomerates. (h,i) Highly magnified images 
in figure (g) showing the adsorption of TSN near fibrin fiber (h) and 
entanglement of TSN agglomerates within the fibrin fiber. (j) Carbon and 
(k) silicon elemental mapping of the image (g) by EDS. (l) EDS spectra 








Figure 2.13. TEM images showing the adsorption of the TSN near and 




Figure 2.14. Procedures of evaluating hemostatic effects. After 
abdominal incision, the left lobe of the liver was placed on a hydrophobic 
film (Parafilm). An 18-gauge needle was advanced into the liver. 
Immediately after withdrawing the needle, prepared cotton swabs 
covered with a Parafilm and a filter paper were put onto the wound and 
manual compression was applied. On the other hand, prepared TSN or 
CA-Lp was injected during the withdrawal of the needle, and bleeding 






Figure 2.15. (a) Photographs of a stab wound after conducting each 
hemostasis procedure: direct pressure (left), applying TSNs (right). (b) 
Amount of bleeding during each hemostasis procedure. (*p < 0.05, and 
n.s., not significant p > 0.05, Student’s t-test.) 
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2.3.3 Contrast enhancement in various medical modalities 
The contrast effects of TSNs on fluoroscopy, CT, and ultrasonography 
were compared to those of SiO2 NPs, CA-Lp, and a commercially 
available iodine contrast agent (Iopamidol). Since X-ray absorption of 
the contrast agents results in signal attenuation on fluoroscopy, their 
contrast effects were assessed by signal-to-noise ratios (SNR) (Figure 
2.16). The X-ray fluoroscopic image reveals that TSNs significantly 
attenuate incident X-ray beam, showing a contrast efficiency comparable 
to that of iodine-containing CA-Lp. The SNR of TSNs is 15 times higher 
than that of SiO2 NPs, demonstrating that the TaOx core is responsible 
for the high X-ray attenuation. To evaluate the detection limit of TSNs 
on CT, we compared the CT numbers (Hounsfield unit, HU) of serially 
diluted solutions with different TSN concentrations (Figure 2.17a, d). 
The contrast effect increases linearly as the concentration increases, and 
both TSNs and iopamidol are distinguishable from water down to a 
concentration of 12.5 mg ml-1. The contrast efficiencies of TSNs and 
iopamidol, calculated from the slopes of X-ray fluoroscopy SNR versus 
concentration, are 0.18 mg-1 ml and 0.17 mg-1 ml, respectively, while 
SiO2 NPs exhibit a negligible contrast enhancement effect (1.8 × 10-4 
mg-1 ml). The CT contrast enhancement effect of TSNs was also 
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evaluated by the slope of CT number versus concentration and compared 
with those of iopamidol and SiO2 NPs. The contrast enhancement of 
TSNs is 18.6 HU mg-1 ml, which is 1.5 and 150 times higher than those 
of CA-Lp (12.9 HU mg-1 ml) and SiO2 NPs (0.12 HU mg-1 ml), 
respectively (Figure 2.17b, e). The stronger contrast effect of TSNs in 
CT can be attributed to the higher X-ray photon energy used in CT 
(applied voltage is 140 kV) compared to that used in fluoroscopy (60 
kV), and the well-matched K-edge value of tantalum (67.4 keV) 
compared with that of iodine (33.2 keV).[31]  
The high mass density of TSNs compared with that of water and 
flesh offers an effective scattering of US-waves, allowing for the use of 
TSNs in ultrasonography-guided procedures. The contrast enhancements 
of TSNs and SiO2 NPs were investigated using an agarose phantom 
loaded with different concentrations of the nanoparticles (Figure 2.17c, 
f). The US signal of TSNs is distinguishable from the background 
starting from a nanoparticle concentration of 8 mg ml-1, and the signal 
enhancement of TSNs is three times higher than that of SiO2 NPs. It is 
well known that the back-scattered US generated from Rayleigh 
scattering is affected by the material size, compressibility and density 
difference from environment.[52] Therefore, not only a larger 
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hydrodynamic size of TSNs (20.4 nm) than that of SiO2 NPs (16.4 nm) 
but also a high density of the TaOx core (~8.18 g cm-3) contributed to the 
more intense US signals in comparison to those of SiO2 NPs, enabling a 
much lower detection limit. 
The in vivo contrast enhancement of TSNs in different imaging 
modalities was assessed using the aforementioned liver puncture model. 
As the contrast effects of TSNs and CA-Lp on fluoroscopy are similar, 
the liver columns filled with each glue exhibit almost identical contrast 
in the fluoroscope images (Figure 2.18a). Notably, the glues are clearly 
distinguished from the ribs with a similar thickness, which can be 
advantageous in clinical situations. Similarly, CT imaging reveals that 
the mean HU value of TSNs is 1.8 times greater than that of the vertebrae 
and slightly higher than that of CA-Lp (Figure 2.18b). Since it is hard to 
compare directly the contrast enhancements on ultrasonography in a rat 
due to the small size of its liver, the contrast enhancement of TSNs, CA-
Lp, and SiO2 NPs was investigated using the calf liver injected with each 
glue at a depth of 4 cm. The bright mode (B-mode) ultrasonography 
imaging shows that the signals from SiO2 NPs and TSNs are bright 
enough to be distinguished from the background liver tissue. Although 
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the reflection of US waves from the CA-Lp applied tissue could be 




Figure 2.16. Contrast enhancement on X-ray fluoroscopy (a) an image 
of the tubes containing water (Ref.), commercial silica nanoparticle 
solution (SiO2 NPs, 50 wt%), mixture of cyanoacrylate adhesive and 
iodized oil (CA-Lp, 75% of Lipiodol, 360 mgI ml-1), and TSNs (40 wt%); 
(b) plots of the calculated signal to noise ratio). (c) Mean shear stress of 
cyanoacrylate (CA; Histoacryl) and cyanoacrylate-Lipiodol mixture 
(CA-Lp) with a volume ratio of 1:1 and 1:3. (d) Fluoroscopy image of 
applied adhesives in agarose gel. White dashed circle indicates the 





Figure 2.17. Comparison of the contrast effects on fluoroscopy, CT, and 
ultrasound imaging. (a) Fluoroscopic images of the microtubes 
containing Iopamidol, SiO2 NPs, TSNs with various concentrations. (b) 
CT images of the microtubes containing the Iopamidol, SiO2 NPs, and 
TSNs. (c) Ultrasound images of the agarose phantom containing NPs 
with various concentration. (d) Plots of the signal-to-noise ratio increase 
depending on the concentration. (e) Plots of the CT values of the 
Iopamidol (red), SiO2 NP (green), TSN (blue) calculated from CT images 
(b). (f) Plots of the signal intensity increase of the SiO2 NPs (green), 
TSNs (blue) from ultrasonography (c). 
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Figure 2.18. in vivo images of a Sprague Dawley (SD) rat after 
application of TSNs and CA-Lp on fluoroscopy (a) and CT (b). On the 
CT image (b), the mean CT values (Hounsfield unit, HU) of each region 
of interest (TSN, CA-Lp, and bone) were measured. (c) Ultrasonography 




One of the major hurdles for intracorporeal use of CA-Lp is its severe 
toxicity and the inflammatory reactions caused by the by-products of 
CA-Lp such as formaldehyde.[5,53,54] Recent reports, however, have 
shown that both SiO2 and TaOx nanoparticles are highly biocompatible. 
Moreover, tantalum-based stents and implants, and tantalum powder-
containing embolic materials (Onyx; Covidien, Irvine, CA) are 
frequently used in clinics thanks to their biocompatibility.[23,27,41,55,56] To 
ensure the biocompatibility of TSNs, their cytotoxicity was evaluated 
using cell morphology analysis and viability assays. To mimic in vivo 
glue application conditions, a small drop of glue-gel was placed at the 
bottom center of a culture dish, upon which a cell suspension was added. 
After 24 h, most of the cells incubated with the TSNs were attached to 
the plate surface regardless of their distance from the gel, while the cells 
near CA-Lp failed to attach to the plate surface and exhibited a round 
shape (Figure 2.19a). Methylthiazole tetrazolium (MTT) assay shows 
that the viability of the cells incubated with CA-Lp decreases in a dose-
dependent manner while those cells incubated with TSNs exhibit little 
cytotoxicity up to a concentration of 800 µg ml-1, demonstrating 
excellent biocompatibility of TSNs (Figure 2.19b). SiO2 NPs have a 
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lower cytotoxicity than CA-Lp, but they still show a significant 
cytotoxicity at a high concentration of 800 µg ml-1. Since SiO2 NPs are 
known to induce hemolysis, the hemolysis effects of TSNs were 
investigated. As shown in Figure 2.19c, most of the red blood cells were 
lysed at a SiO2 NP concentration of 100 μg ml-1, but the hemolysis rate 
by TSNs was much lower.  
Because both TSNs and SiO2 NPs have similar silica structure, 
the observed difference in their hemolytic effect is unexpected. To 
understand the difference of their hemolysis effect, we evaluated the 
influence of the nanoparticle size, the amount of fluorescent dye, and the 
thickness of silica shell on hemolysis rate. Hemolysis rate of silica 
nanoparticles with sizes of 22 nm, 30 nm, and 105 nm reveals that the 
largest 105 nm-sized NPs exhibit lower hemolysis rate than that of the 
22 nm- and 30 nm-sized silica nanoparticles (Figure 2.20), which is 
consistent with the previous report.[57,58] The amount of incorporated dye 
does not affect the hemolysis rate of TSNs and SiO2 NPs 
(Supplementary Fig. 13d, e, and f). Most strikingly, TSN-5 with 5 nm-
thick silica shell show much higher hemolysis rate than TSNs with 1 nm-
thick silica shell and TaOx NPs without silica shell (Figure 2.20h). 
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In the previous reports, hemolysis by silica nanoparticles was 
attributed to the direct interaction between the cell membrane and silanol 
groups on the nanoparticle surface[57,58], and the mesoporous silica 
nanoparticles are known to exhibit lower hemolytic effect than dense 
silica nanoparticles. The microporous structure of TSNs seems to be 
responsible for their lower hemolysis rate compared to that of the dense 
silica nanoparticles (see the gas adsorption data in Figure 2.21). 
In vivo biocompatibility of TSNs was assessed by histologically 
analyzing the tissues after applying TSNs or CA-Lp in a liver puncture 
model (Figure 2.22 and Figure 2.23). A significant difference in the 
level of tissue inflammation was observed between the biological tissues 
treated with TSNs and those with CA-Lp. Consistent with the previous 
reports, an immediate immune reaction was identified around the CA-Lp 
applied regions within 3 days, and this response developed to a severe 
inflammation in and around the adhesives at 14 days, and persisted over 
56 days.[54] In contrast, the TSN was observed to be innocuous, which is 
consistent with the previous report on the inertness of tantalum. As the 
tantalum oxide is a chemically stable material, the degradation of TSNs 
is slow compared to that of polymer adhesives as shown in histological 
analysis.  
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The inertness of the tantalum oxide in TSNs was also supported 
by the extremely slow dissolution of tantalum in body fluid (Figure 2.24). 
Only little portion spreads to other organs including liver, spleen, and 
lung, and most of the nanoparticles (>99.5%) remains in the applied 
position (Figure 2.25). Over six weeks, there was no adverse effect in 
our blood test, proving their long-term biocompatibility in vivo (Figure 
2.26). Considering the intracorporeal use of adhesives for image-guided 
procedures, their low cellular toxicity, low inflammatory reaction 
derived from the chemical stability of oxides, and proved long-term 






Figure 2.19. (a) Cellular morphology of mammalian cells (HeLa cell 
line) incubated where the TSN (left) or CA-Lp (right) glue was applied. 
(b) Viability of cells treated with TSNs, SiO2 NPs, and CA-Lp. (c) 
Concentration-dependent hemolysis rate of TSNs, SiO2 NPs, and TSN-5 
with 5 nm-thick silica. Error bars indicate standard deviations (n = 3, *p 





Figure 2.20. Comparative study of hemolysis effects of TSNs, SiO2 
NPs, TaOx NPs. (a) TEM images of TaOx NPs-120 nm, SiO2 NPs-105 
nm, and SiO2 NPs-22 (b) Quantification of rhodamine attached onto the 
TSN, SiO2 NP-30 (Ludox TM-50; TEM image in Supplementary Figure 
4d), and SiO2 NP-105, prepared with low (LD) and high (HD) dye 
concentration. (c) Hemolysis rate of silica nanoparticles with sizes of 22 
nm, 30 nm, and 105 nm reveals that the largest 105 nm-sized NPs exhibit 
lower hemolysis rate. (d-f) Hemolysis rates of TSNs, SiO2 NP-105, and 
SiO2 NP-30 with different amount of rhodamine dye incorporation reveal 
that the amount of incorporated dye does not affect the hemolysis rate. 
(g) Hemolysis rate of TaOx NPs with sizes of 11 nm and 120 nm reveals 
that both TaOx NPs exhibit negligible hemolysis effect. (h) TSNs with 
thicker silica shell exhibits higher hemolysis rate than TSNs with thinner 




Figure 2.21. Gas adsorption analysis of TaOx/SiO2 NPs with 1 nm-thick 
silica shell (denoted as TSN), SiO2 NP, TaOx NP, TaOx/SiO2 NPs with 5 
nm-thick silica shell (denoted as TSN5) (a) N2 adsorption-desorption 
isotherm of TSN, SiO2 NP, TaOx NP, and TSN12. (b-c) Cumulative pore 
volume and pore size distributions. The black arrows indicate the 
microporous structure of TaOx NPs. (d-e) enlarged plots showing the 
micro-pore region. The mirco-pore region is shaded with yellow box. 




Figure 2.22. Histological analyses for biocompatibility of TSN. Tissue 
specimens stained with hematoxylin and eosin (H&E) (a) 3, (b) 14, (c) 




Figure 2.23. Histological analyses for biocompatibility of CA-Lp. 
Tissue specimens stained with hematoxylin and eosin (H&E) (a) 3, (b) 








Figure 2.24. The concentration of dissolved Ta from TSNs in simulated 





Figure 2.25. Average concentration of tantalum element in tissues 
obtained at 3, 7, 21, and 42 days after the application of TSNs as 
hemostatic agent for liver puncture models (a), and as fiducial marker 




Figure 2.26. Long-term complete blood count (CBC) results for WBC, 
RBC, HGB, and PLT. Long-term serum biochemistry results for BUN, 
CREA, ALP, AST, ALT, and CRP from the Sprague Dawley rats (n=5). 
The analyses were proceeded after applying glues (TSNs, CA-Lp) to the 




2.3.5 Real-time image-guided procedures 
To investigate the potential of TSNs for image-guided surgery, we 
conducted two surgical demonstrations to show their utility not only as 
an adhesive for medical intervention with real-time imaging modalities 
but also as an anatomical marker to guide resection and/or radiotherapy. 
The liver puncture model was performed in a rabbit without abdominal 
incision under the guidance of fluoroscopy and ultrasonography (Figure 
2.27). Using dynamic X-ray fluoroscopic imaging, we could distinguish 
TSNs from other organs including vertebrae, in spite of low X-ray energy 
and short exposure time (60 kV and 1 ms, respectively). In 
ultrasonography, the TSNs that filled the liver track appeared as a bright 
area. Moreover, there was no bleeding through and on the skin, 
indicating successful hemostasis of connective tissues and dermal 
wounds. Thus, TSNs can support minimally invasive real-time 
procedures with their greatly enhanced contrast effect, enabling both 
multimodal imaging capability and adhesive property. 
In addition to the potential of TSNs as a tissue adhesive, TSNs 
were also applied as a surgical marker (also called as a fiducial marker) 
in image-guided procedures. In image-guided procedures or radiotherapy, 
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the movement of soft tissues often hinders localizing and registering an 
operative region. Some metal-based solid implants, such as a small gold 
rod or coil, have been used as markers of soft tissues.[11] However, their 
large physical dimensions usually require complicated insertion 
procedures that increase the risk of adverse events,[59] and those solid 
implant markers usually cause streaking artifacts in CT imaging.[60] 
Although injectable liquid fiducial markers have been proposed, their 
unwanted migration can lead to serious localization errors as well as 
complications in distant tissues. To compare mobility, five different 
fiducial markers including TSNs, gold rod, metal coil, Lipiodol, and CA-
Lp were implanted in calf lung and liver samples ex vivo and these 
samples were subsequently shaken and CT images are compared. Unlike 
other materials which incited strong artifacts (gold rod, metal coil) or 
which moved substantially (Lipiodol), TSNs were immobile during the 
experiment and caused only negligible artifacts on CT imaging (Figure 
2.28 and Figure 2.29). TSNs are ideal fiducial markers due to their 
detectability by various imaging modalities and their strong adhesion to 
soft tissues. Moreover, for optical imaging, the fluorescent dye 
molecules conjugated on TSNs can prevent the rapid dye diffusion that 
usually results in the blurring of injection sites.  
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To check the reliability of the TSNs as a fiducial marker within 
actively moving tissues, TSNs were injected into the thigh and calf 
muscles of rats. The injected TSNs could be clearly visualized by CT and 
fluoroscopy, and their positions and shapes were retained during the 
flexion and extension of the leg (Figure 2.30). Micro-CT images showed 
that the locations of the TSN markers did not change over two weeks 
(Figure 2.31). In addition, TSNs in the muscle were readily detected by 
fluorescence imaging (Figure 2.30c), which can help surgeons recognize 
a surgical target and perform a safe and accurate operation.[61]  
Lastly, the feasibility of the TSN marker was evaluated with a rat 
model of syngeneic lung cancer. Indeed, fiducial markers are usually 
required for successful resection and radiotherapy of lung cancer, but its 
placement in the lung is challenging because of risks such as migration 
and distant embolism via the pulmonary veins.[62,63] Localizing and 
marking of target lesions with rhodamine-attached TSNs were conducted 
with the aid of CT (Figure 2.31b). Neither abnormal breathing nor 
behavior was observed during and after the procedures. TSNs were 
clearly identified in the index tumors on both fluoroscopy and CT 
(Figure 2.30). The opacity of TSNs was high enough to be clearly 
distinguished from the nearby ribs and vertebrae of the rat. After thoracic 
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incision, fluorescence signals of the rhodamine-attached TSNs were 
clearly observed from the lesion (Figure 2.30g). Both the radiopacity of 
the TSNs and the high fluorescent signal from rhodamine would help in 
guiding the resection of the lesion. Considering that the leg and lung 
move vigorously by the physiological motion of rats, the retention of 





Figure 2.27. Series of schematic drawings, still images of operation-
video, real-time fluoroscopic video, and ultrasonography. Each step 
represents; (i) making a stab wound with a needle, (ii) applying TSNs for 
hemostasis during withdrawal of the needle, and (iii) imaging for the 
post-procedural validation. On the images, blue and yellow arrows 







Figure 2.28. Mobility evaluation of fiducial markers including TSNs, 
gold rod, metal coil, Lipiodol, and CA-Lp. Three-dimension rendered X-
ray CT images of the liver (a) and lung (b) which contains various 
fiducial markers. (c) CT images of each marker. The streak artifacts 





Figure 2.29. Top views of the (a) liver and (b) lung showing the positions 
of the fiducial markers and needles, before shaking (top) and after 
shaking (bottom). Black arrows indicate needle tips, and dashed circles 
indicate the markers. Average migration distances of markers in the (c) 




Figure 2.30. Multimodal imaging of the TSNs as an injectable fiducial 
marker implanted to the calf muscles of a SD rat. (a) Transversal micro-
CT image showing the location of TSNs near the fibula (calf bone). (b) 
Fluoroscopic image of the implanted TSNs along with the fibula. (c) 
Fluorescent weighted image of the same region. (d) A series of still cuts 
of fluoroscopic video. (Blue arrows indicate the TSN markers, and the 
numbers in the picture represent the time of each frame.) Multimodal 
imaging of the percutaneously injectable TSN marker in rat lung cancer. 
(e) Axial image of CT. (f) Lateral view on fluoroscopy. (g) Fluorescence 




Figure 2.31. (a) 3D-rendered micro-CT images of the TSN-marked leg 
muscles of a rat; imaged right after the implementation, after 2 days 
passed, and after 2 weeks passed. The two blue arrows indicate the TSNs 
markings in the thigh and calf muscles along with the fibula and femur. 
(b) Multiplanar-reformatted CT images during percutaneous lung tumor 
marking procedure with fluorescent TSNs. The needle and injected TSNs 




Due to the recent development of medical imaging techniques and 
interventional devices, many surgeries have been aided by image-guided 
and minimally-invasive procedures. For example, conventional surgeries 
for vessel occlusion, bleeding control, internal organ biopsy, spondylosis, 
and some early-stage tumors (e.g., hepatocellular carcinoma) are being 
replaced by percutaneous angioplasty, catheter-directed embolotherapy, 
needle biopsy, vertebroplasty, and radiofrequency/microwave ablation, 
respectively, all of which are conducted under the guidance of medical 
imaging. 
However, nanomaterials relevant to the image-guided procedures 
are rarely suggested for use in medical practice. Ideally, they should be 
identifiable on clinical imaging (e.g., X-ray fluoroscopy, CT, US, and 
magnetic resonance imaging), convenient to apply percutaneously with 
a catheter or needle, biocompatible to minimize adverse reactions in 
body, and able to achieve surgical goals (e.g., hemostasis, tissue adhesion, 
and tissue marking). Given the unique possibilities of nanomaterials, 
including high image contrasting effects, adhesive properties, and 
dispersibility in various fluids, biocompatible NPs have enough potential 
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to replace the conventional materials used in image-guided procedures. 
In this context, TSNs can be a representative material that satisfies 
various requirements for medical applications by providing imaging 
capability, convenient administration, biocompatibility, and 
effectiveness.  
The inertness of tantalum oxide not only provides good 
biocompatibility, but also hinders its biodegradation in body. Unlike 
typical imaging studies by systemic intravenous administration of 
contrast agents, image-guided procedures usually require a very small 
quantity of NPs. Compared with the required amount of Tantalum used 
as an intravenous CT contrast agent (840 mg kg-1)[41], our study utilized 
less than one fiftieth of Tantalum (15 mg kg-1), which accounted for only 
0.02 ~ 0.05 ml. Moreover, almost all TSNs are remained in the target 
areas without severe adverse reactions, suggesting that the systemic 
effects of TSNs can be minor, when administered locally with image 
guidance. 
As a fiducial marker prior to a surgery, poor biodegradability 
hardly causes a problem because both the index tumor and the marker 
will be removed together (en bloc). In radiotherapy, persistent marking 
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of an index tumor facilitates the consistent targeting and follow-up 
during serial treatments. As a non-degradable tissue adhesive and a 
fiducial marker, TSNs exhibit substantially ameliorated inflammatory 




In conclusion, we designed and synthesized multifunctional and 
biocompatible tantalum oxide/silica core/shell nanoparticles (TSNs) 
composed of radiopaque tantalum oxide core with multimodal imaging 
capability and silica shell with a strong tissue adhesive property. As 
designed, the TSN glue is clearly visualized by clinical imaging 
modalities including X-ray fluoroscopy, CT, and ultrasonography, and 
exhibits adhesive property similar to that of the CA-Lp. Furthermore, the 
TSNs cause much less cellular toxicity and less inflammation than the 
clinically-used CA-Lp, which is very important for intracorporeal use of 
adhesives for image-guided procedures.  
The current studies demonstrate the applications of TSNs to 
hemostatic adhesive for minimally invasive procedures and as 
immobilized marker for image-guided procedures by combining their 
multifunctional characteristics and tissue adhesive property. Given the 
needs of various tissue adhesives in medicine, our results give additional 
insights on biomedical applications of designed multifunctional 
nanoparticles, which can be expanded to image-guided procedure and 
regenerative medicine as well as drug delivery and cancer diagnosis. 
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**Most of the contents of this chapter were published in the article, 
“Multifunctional nanoparticles as a tissue adhesive and an injectable 
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Chapter 3. Imaging and drug delivery assisting cell 




Cell-based therapies involving transplantation and direct injection have 
provided a prospective solution for the treatment of congenital defects 
and damaged tissues.[1,2] However, declines in survival rate and 
therapeutic effect of administered cells due to host immune rejection 
substantially limit the extensive application of cell-based therapy, so a 
suitable method is required to track/monitor the administered cells to 
evaluate the efficacy of cell therapy. Hence, incorporating 
biomaterials/nanomaterials to cells has been spotlighted in cell-based 
therapies as a strategy to provide therapeutic cells with a protective layer 
or to tag them with imaging probes.[3-15] In addition, incorporating drug-
loaded nanoparticles are expected to enhance the efficiency of drug 
delivery because of their active targeting capability.[16-19]  
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One of the main approaches for the incorporation of exogenous materials 
is cell surface modification via chemical conjugation to functional 
groups existing on the cell membrane.[5,19-24] Compared to other cell 
surface engineering methods, this approach enables direct engraftment of 
various materials, and guarantees their stable attachment to cells when 
they are implanted into the complex biological environment. The 
conjugation based surface engineering can modify individual cells 
uniformly and stabilize them without aggregation, unlike 
electrostatically driven cell coating.[4,9] Because the approach does not 
involve hydrophobic interaction, it broadens the selection of the material 
without compromising the solubility and stability of the exogenous 
materials.[25] Based on the well-established bioconjugation techniques, 
the procedure is generally accessible without additional preparation steps 
or special equipment such as microfluidic channels.[15]  
Despite the advantages of conjugation-based modification, the 
introduction of active functional groups on the cell surface remains 
challenging because most cell surfaces do not contain chemically 
reactive moieties.[26] Although amide coupling can be employed for cell 
surface modificaion[27-29], cross-coupling between carboxylate and 
amine groups potentially decreases both efficiency and specificity of the 
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reaction between coating materials and cell surface. There are some 
reported methods to introduce non-natural functional groups such as 
ketone and azide on mammalian cell surfaces via glycoengineering.[30-32] 
These are time-consuming, taking several days for cells to express them 
and confirming their expression.  
Herein, we report a facile and universal method for cell surface 
engineering that exploits disulfide bonds on cell membranes[33] for 
subsequent thiol-maleimide conjugation. A variety of cell types can be 
coated without any adverse effects on cell functions. This method can 
coat biomolecules and polymers to demonstrate rapid formation of 
multicellular assembly and facilitation of cell adhesion to a polymeric 
scaffold. Fluorescent multifunctional nanoparticles can be attached to 
cell surface for tracking the administered cells and delivering adjuvant 
drugs simultaneously. Finally, synergistical enhancement of cellular 
activity is achieved through a dual coating of polymer and nanoparticles.  
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3.2 Experimental Section 
 
3.2.1 Cell culture and preparation 
HeLa, Jurkat, C2C12, and neuro-2A cells were purchased from the 
Korean Cell Line Bank (Korea). All cells, except induced neuronal stem 
cells, were cultured in tissue-culture plates with high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco-BRL, USA) containing 10% 
fetal bovine serum (FBS; Gibco-BRL), 1% L-glutamine (200 mM, 
Gibco-BRL), and 1% penicillin-streptomycin (10,000 U/ml of penicillin 
and 10,000 g/ml of streptomycin, Gibco-BRL). When the cells reached 
80% confluency, they were washed twice with phosphate-buffered saline 
(PBS; pH 7.4, Gibco-BRL). For experiments using detached cells, 
trypsin-ethylenediaminetetraacetic acid (EDTA) solution (0.25% trypsin, 
380 mg/L EDTA-4Na∙2H2O; Gibco-BRL) was added to the culture plate, 
which was then incubated at 37 °C for 3 min. After the cells were 
detached from the plate, DMEM was added for neutralization. The cells 




3.2.2 Reduction disulfide bonds of proteins on cellular surface 
Cells at a density of 2 × 106 cells/ml were collected in 1.7-ml tubes by 
centrifugation at 300 gravitational force and suspended in 1 ml of PBS 
containing 0.5, 1, 2, or 3 mM of Tris(2-chloroethyl) phosphate (TCEP , 
Sigma-Aldrich, USA). Then the samples were incubated at 37 °C for 20 
min. After incubation, the cells were washed with PBS twice. For the 
certification of free thiols, Ellman’s assay (5,5-dithio-bis-(2-
nitrobenzoic acid), Thermo, USA) was performed following the 
manufacturer’s procedure. The cell viability was measured by 
Live/Dead® viability/cytotoxicity kit (Thermo) that contains calcein-
AM and ethidium homodimer solution. After treatment of TCEP for 20 
min on cells, Live/Dead assay were used to indicate live cells and dead 
cells. Then the cells were imaged by fluorescence microscopy (EVOS® 
Cell Imaging Systems, Thermo) and counted in separate 5 fields. For 
proliferation, cells were stained using the ClickiT ® EdU Alexa Fluor® 
488 Imaging Kit (Thermo). Prior to EDU assay, cells were cultured 
overnight in serum free media for the synchronization of cell growth. 
After synchronization, cells were treated with reductant and incubated in 
EDU containing growth media for 3 hrs. Then, EDU assay kit was 
applied to indicate cells in S phase and analyzed by flow cytometry. To 
144 
assess cell metabolism, cells were incubated with the growth media 
containing the alamarBlue® Cell Viability Reagent (Thermo). The 
relative absorbance difference was measured on same time each day. For 
morphological analysis, cells were fixed with 4% paraformaldehyde 
(Sigma-Aldrich) for 10 min and permeabilized with Triton X-100 
(Sigma-Aldrich) for 10 min. Fixed cells were stained with DAPI 
(Thermo) for 10 min and Alexa Fluor® 594 Phalloidin (1:200 dilution, 
Thermo) for 2 hrs. 
 
3.2.3 Maleimide Alexa Fluor 488 (MFluor) Coating 
After TCEP treatment, HeLa cells were washed with PBS twice. Then, 
Alexa Fluor® 488 C5 Maleimide (MFluor; 1 mg/ml, Thermo) was diluted 
in PBS solution (final concentration: 3 µg/ml) and added to the cells, 
which were then incubated for 20 min in an incubator at 37 °C. During 
incubation, the tubes were tapped every 5 min. After 20 min, the cells 
were washed with PBS twice and analyzed by confocal microscopy 
(LSM 780; Carl Zeiss) and flow cytometry (FACS Aria II; BD 
Biosciences, USA). For confirmation of surface coating, the PKH26 Red 
Fluorescent Cell Linker Kit (PKH26; Sigma-Aldrich) was used. For flow 
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cytometric analysis, a fluorescein isothiocyanate (FITC) standard signal 
was set. 
 
3.2.4 Pre-conjugation of dye-silane derivatives  
Fluorescent dye-silane derivatives were prepared in advance by 
conjugation of (3-aminopropyl)triethoxysilane (APTES, Sigma-Aldrich) 
and fluorescent dyes, including FITC(Sigma-Aldrich), cyanine 5 NHS 
ester (Cy5; Lumiprobe), and cyanine 5.5 NHS ester (Cy5.5; Lumiprobe). 
Each dye with fucntional group was dissolved in ethanol at 3 mM 
concentration with APTES at 15 mM. The mixture was shaken at room 
temperature overnight. 
 
3.2.5 Preperation of fluorescent mesoporous silica nanoparticles  
Uniform MSN were synthesized as previously reported4 with slight 
modification. Two grams of hexadecyl trimethyl ammonium chloride 
(cetyltrimethylammonium chloride solution 25%, 8 ml, Sigma-Aldrich) 
and 80 mg of triethanolamine were disolved in 20 ml of distilled water. 
After the solution was heated at 95 °C for 1 h, 1.5 ml of tetraethyl 
orthosilicate (Acros Organics) was added dropwise. To prepare 
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fluorescently labeled mesoporous silica nanoparticle (MSN), the pre-
conjugated dye-silane derivatives were subsequently added. Reactions 
were proceeded for 50 min, resulting in turbid solutions, and 50 mg of 
APTES was added and reacted for 10 min for amino-functionalization of 
the MSN. The products were collected by centrifugation and re-dispersed 
with ethanol several times. For extraction of residual surfactant in MSN, 
the products were dispersed and stirred in 1 wt% of NaCl in methanol at 
60 °C for 3 h, and the same extraction process was repeated twice. The 
final products were dispersed in ethanol at 10 mg/ml.  
 
3.2.6 PEGylation of amino-fucntionalized MSN for cell coating 
Maleimide-PEG 5k succinimidyl NHS acid ester (Mal-PEG5k-SCM), 
and methoxy-PEG5k succinimidyl glutarate ester (mPEG5k-SG) were 
purchased from Creative PEGworks and SunBio, respectively. PEG 
derivatives were pre-dissolved in dimethylformaldehyde at 100 mg/ml. 
For maleimide-fucntionalized MSN (Mal-MSN), 15 mg of MSN 
dispersed in ethanol, 10 mg of mPEG-SG, and 5 mg of Mal-PEG-5k-
SCM was mixed and shaken at room temperature overnight. After the 
conjugation, residual PEG was washed away by centrifugation and the 
products were redispersed in PBS. MSN without fucntional group was 
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prepared using the same method, except that 15 mg of mPEG-SG was 
used. 
 
3.2.7 Characterization of MSN 
Transmission electron microscopic (TEM) images were obtained with an 
EM-2010F (Jeol, Japapn). Hydrodynamic radius was analyzed with a 
size analyzer (Nanozs). The absorption and emission spectra of the 
fluorescently labeled MSN was measured with SpectroV-550 and FP-
5500 instruments (both Jasco, Japan).  
 
3.2.8 Attachment of the MSN to mammalian cells 
After mild reduction of the cell surface with TCEP at 0.75 mM, the cell 
suspension was washed several times with PBS and incubated in 5 mg/ml 
of Mal-MSN solution for 20 min. Subsequently, mPEG2k-SH (methoxy 
PEG2k-thiol) dissolved in PBS was added to the suspention at a 
concentration of 1 mg/ml, and incubated for 10 min to deactivate the 
maleimide groups on the nanoparticles. The MSN-coated cells were 
seperated from residual nanoparticles by centrifugation and then washed 
with PBS several times. Depending on the imaging device, FITC-, Cy5-, 
or Cy5.5-labeled MSN was used. For dual-coating with MSN and PEG, 
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5 mg/ml of mPEG 2 kDa maleimide dissolved in PBS was introduced to 
the MSN coated-cell suspension. The confocal microscope image were 
obtained using LSM 780 and Cy5 conjugated MSN. The fluorescence 
signal difference of cells was measured by flow cytometry by using FITC 
conjugated MSN (BD AccuriTM C6 Plus Cytometer System; BD 
Biosciences). 
 
3.2.9 Drug or fluorescent dye loading into MSNs and their 
characterization 
One milligram of rhodamine 123, fluorecein or dexamethasone 21-
phosphate disoldium salt dissolved in PBS was added to 5 mg of 
PEGylated MSN and shaken at room temperature for overnight. 
Excessive rhodamine or dexamethasone was washed by centrifugation 
and the final product was dispersed in PBS. The fluorecent dye 
(rhodamine 123 or fluorecein) loaded MSN was also analyzed with 
fluorescence correlation spectroscopy equiped on confocal microscopy 
(Zeiss LSM 780 NLO, Zeiss, Germany) and applied to coat HeLa cell 
with the same used methode, to confirm the surface modification. The 
coated cells were also visualized with the confocal microscope. The 
functionalized MSN was transferred into a 1-kDa dialysis tube and stored 
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in 40 ml of PBS to analyze its release profile. The permitted small 
molecules were analyzed by spectrophotometry using a Spectro V-550 
or a Victor X4 microplate reader (Perkin-Elmer, USA). 
 
3.2.10 Electron microscopic imaging of coated cells 
Electron microscopy samples were prepared by fixation and dehydration. 
Coated Hela cells were fixed with 2.5% of glutaraldehyde and 2% of 
paraformaldehyde in 0.1 M of sodium cacodylate buffer (pH 7.4), then 
rinsed with cacodylate buffer. Additional fixation was carried out with 1% 
osmium tetraoxide in cacodylate buffer. After washing away the residual 
fixation reagent with distilled water three times, cells were stained 
overnight with 2% uranyl acetate solution. Dehydration was done 
gradually by incubating the stained cells for 10 min in each of 30%, 50%, 
70%, 80%, 90% ethanol, absolute ethanol, and propylene oxide. The 
dehydrated cells were suspended in 50% Spurr’s resin with propylene 
oxide for 2 h, and in Spurr’s resin overnight. After fresh Spurr’s resin 
was added to the cell suspension, the resin was hardened in oven at 60 °C 
for 24 h. The embedded cells were sliced with an ultramicrotome (EM 




3.2.11 Evaluation on accessibility to cellular membrane after surface 
modification 
After the surface modification of HeLa or RAW264.7 cells, the cells 
were washed four times with PBS. The cells were stained with CellMask, 
CD44-antibody, or CD11b with appropriate condition. The control group 
or surface-modified group were incubated for 10 min at 4 °C with 
CellMask (for HeLa cell, 1:2000, Thermo Fisher Scientific), for 30 min 
at 37 °C with anti-human CD44 (for HeLa cell, 1:200, BD Pharmigen), 
at 4 °C with FITC anti-mouse/human CD11b Antibody (for RAW 264.7 
cell, 1:2000, BioLegend). To the CD44 antibody, fluorescent secondary 
antibody (FITC Goat anti-Mouse IgG (1:1000, Bethyl Lab. Inc.)) was 
treated for 30min at 37 °C. Prior to imaging or flow cytometry analysis, 
residual fluorescent antibody or CellMask were removed by washing 
four times with PBS. The cells were re-suspended in PBS for flow 
cytometry (BD AccuriTM C6 Plus Cytometer System; BD Biosciences, 
BD Biosciences, USA). The corresponding fluorescence images were 
acquired using a Zeiss LSM 780 NLO inverted laser scanning confocal 
microscope (Zeiss, Germany). 
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3.2.12 Animals and Cells 
In this study, we used male BALB/c nude and Crl:CD-1 (ICR) mice 
weighing 28–30 g (Orient, Seoul, Korea). The animals were maintained 
at 22–24 °C under a 12-h/12-h light/dark cycle. The mice were given at 
least 1 week to adapt to their environment prior to experiments. The 
Institutional Animal care and Use Committee at the Korea Basic Science 
Institute (KBSI-AEC 1601) reviewed and approved this study. All 
animal procedures were in accordance with the Guide for the Care and 
Use of Laboratory Animals issued by the Laboratory Animal Resources 
Commission of KBSI. HeLa-Luc (Xenogen) human cervical 
adenocarcinoma cancer cells were grown at 37 °C in DMEM (Lonza) 
containing 10% (v/v) FBS (Gibco-BRL).  
 
3.2.13 Intra-vital imaging 
For the implantation of a dorsal skin-fold chamber into mouse, two 
plastic frames were implanted into extended double layers of skin. One 
layer of the skin was removed in a circular area of approximately 13 mm 
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in diameter. One milligram of rhodamine 123 were loaded to 5 mg of 
PEGylated MSN and the excess rhodamine dye were removed by 
washing procedure with PBS. One million of Hela cells were coated with 
rhodamine 123 loaded MSN using the same method described above. 
About 20 μl of rhodamine loaded MNP-coated HeLa cells (1 × 104) 
prepared was implanted at the center of the remaining layer (epidermis, 
subcutaneous tissue, and muscle). A cover glass (12 mm) was then placed 
on the chamber. Dorsal skin-fold chambers were observed under an 
intravital microscope (LSM 780 NLO; Carl Zeiss, Germany, KBSI 
Chuncheon Center, Korea). 
 
3.2.14 In vivo imaging system 
The in vivo fluorescence imaging to track the location of cells was 
obtained by whole body imaging system using Cy5.5 conjugated MSN 
coated HeLa-Luc cells. The cells were reduced by 0.75 mM TCEP and 
incubated in 5 mg/ml of Cy5.5 conjugated Mal-MSN solution for 20 min. 
About 1 × 106 HeLa-Luc cells were injected subcutaneously in each 
group. The fluorescence and luminescence were imaged by IVIS200 
system (Xenogen Corporation, Alameda, CA, USA) for 0-8 days. 
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3.2.15 Implanting cells with drug delivery vehicle and protective 
polymer 
The protection and immunosuppression with polymer/nanoparticle 
coating were evaluated with monitoring subcutaneous injected coated 
cells. For polymer coating, cells were reduced by 1 mM TCEP and 
treated with 10% (w/v) maleimide-PEG (JenKem Technology, TX, USA) 
solution for 20 min and washed for several times. For MSN coating, after 
mild reduction of the cell surface with TCEP at 0.75 mM, the cell 
suspension was washed for several times with PBS and incubated in 5 
mg/ml of (dexamethasone)-loaded Mal-MSN solution for 20 min. Dual-
coating of cells was conducted with the mixture of 10% (w/v) 
maleimide-PEG and 5 mg/ml of (dexamethasone)-loaded Mal-MSN 
solution for 20 min after 0.75 mM TCEP reduction. For the subcutaneous 
primary tumor model, mice were anesthetized by exposure to 2–2.5% 
isoflurane, and 100 µl sterile Dulbecco’s phosphate-buffered saline 
containing 1 × 107 HeLa-Luc cells was injected into the back of each 
mouse. To check viability of the Hela-Luc, luciferin was dissolved in 
PBS (30 mg/ml) and 150 μl of the luciferin solution was intraperitoneally 
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injected. Cellular activities were monitored on the IVIS200 system for 
0–7 days, and the regions of interest were quantified with photon flux 




3.3 Result and Discussion 
 
3.3.1 Activation of thiol group on cellular surface 
Scheme 3.1 describes the surface modification method that consists of 
mild reduction of disulfides on cell surfaces with tris(2-
carboxyethyl)phosphine (TCEP) and subsequent thiol-maleimide 
conjugation. TCEP is nonvolatile and stable in aqueous solution at room 
temperature over a wide range of pH, and resistant to air oxidation.[34] It 
can selectively reduce disulfide bonds, but are essentially unreactive 
towards other functional groups in proteins.[35] Compared to other 
reducing agents such as dithiothreitol and 2- mercaptoethanol, TCEP 
does not react with active maleimide groups, retaining the efficiency of 
cell surface modification. 
Fluorescent dye with a maleimide functional group (MFluor) was 
utilized to evaluate the coating method (Figure 3.1). Fluorescence 
signals were distributed evenly over the cell surfaces without any 
evidence of internalization. When the cells were post-labeled with a 
membrane dye (PKH-26), MFluor signals co-localized with those of 
PKH-26, confirming that the conjugation takes place solely on the cell 
surface. Dose-dependent effects of TCEP on HeLa cells were evaluated 
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by flow-cytometric analysis. The reduction reaction dramatically 
increased the fluorescence of attached MFluor on the cells, which was 
saturated after treatment with 1 mM TCEP (Figure 3.2). In quantitative 
analysis, the ratio of the amount of MFluor to cellular surface area is 
nearly identical in attached or detached state, indicating that the 
conjugation evenly occurs regardless of the cellular morphology. 
(Figures 3.1a and 3.3). Most importantly, no adverse effect on cellular 
morphology, viability, proliferation, and metabolism was observed for 
TCEP concentrations equal or below 1 mM (Figure 3.4), and the reduced 
thiols are recovered in a single day (Figure 3.5). Thus, 1 mM of TCEP 









Scheme 3.1 Cell surface modification with fluorescent dye, polymer, and 





Figure 3.1. Confocal image of Hela cell decorated with MFluor (a) 2D 
orthogonal plane images of detached (left panel) and attached (right 
panel) MFluor-coated HeLa cells obtained by confocal microscopy. (b) 
Confocal microscopic image of cell surface modified with MFluor and 








Figure 3.2. Flow-cytometric analysis for comparison of MFluor 
attachment to HeLa cell depending on the concentration of reductant. 
Control group represents the cells without any treatment including the 







Figure 3.3 Quantification of cell surface reduction by concentration 
dependent reduction and MFluor coating. a) Analysis plot and the 
representative image of attached HeLa cells. b) Analysis plot and the 
representative image of detached HeLa cells. c) Analysis plot of attached 
and detached HeLa cells normalized by the single cell surface area. (*p 
< 0.05 vs. non-treated group, n = 5 in (a) and (b), average surface area of 





Figure 3.4 Evaluation of cytotoxicity depending on the concentration of 
reductant. a) Fluorescence images stained with F-actin (red) DAPI (blue) 
for the cellular morphology analysis depending on the reductant 
treatment. b) Plot of Live/Dead assay for cell viability measurement. c) 
Proliferation rate measurement by EDU assay after synchronizing cell 
growth before reduction. d) Cell metabolism measurement by 
alamarBlue assay (*p < 0.05 vs. non-treated group, **p < 0.01 vs. non-







Figure 3.5 Flow-cytometric analysis onthe recovery of reduced thiols on 
the reduced cells. Control group represents the cells without any 
treatment including the MFluor. Without TCEP group represents the cells 
only treated with MFluor. Day 0 represents cells coated with MFluor 
right after 1 mM TCEP reduction. Day 1 represents cells coated with 
MFluor for a day after 1 mM TCEP reduction.  
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3.3.2 Nanoparticle attachment to cellular membrane 
Nanoparticles have been employed in a wide range of biomedical 
applications, such as bioimaging and delivery of therapeutic cargo.[19,36-
39] In this study, we functionalized cells by coating with nanoparticles for 
tracking, imaging, and localized drug delivery. As one of the 
representative nanomaterial candidates, we chose fluorescent 
mesoporous silica nanoparticles (MSNs) because of their facile surface 
modification, high drug-loading capability, and good 
biocompatibility.[3,40-42] Maleimide-conjugated MSNs were prepared and 
conjugated to the surface-reduced cells (Figures 3.6). The nanoparticles 
were aligned around the cell surface (Figures 3.7). As shown by the flow 
cytometry, a significant number of nanoparticles was attached to the 
surface-reduced cells (Figures 3.8). Compared to non-specific 
adsorption of nanoparticles to the cell surface, the MSNs covalently 
bound to the cells, thus providing sufficient stability to endure multiple 
washing steps (Figures 3.9).  
To investigate whether surface receptors are blocked or sterically 
hindered after the surface modification, we examined the surface 
accessibility and ligand exposure before and after surface modification 
in HeLa cell and RAW 264.7 macrophage cell. First, Cellmask-orange 
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which can target most of lectins on cell surface was used. After cell 
surface modifications including reduction (TCEP treatment), 
nanoparticle coating (mesoporous silica attachment), polymer coating 
(maleimide PEG coating), and nanoparticle/polymer dual coating, we 
analyzed the cells with flow cytometry and confocal imaging. The little 
changes of fluorescence intensity and conformal coating of cell mask 
suggest that the surface lectins of coated cells can be accessible to 
Cellmask and confirm that blocking by the coating material is also 
negligible (Figure 3.10).  
Furthermore, we examined the effect on glycoprotein or protein 
of the TCEP-mediated reduction and cell surface modification. The 
CD44 antigen, a glycoprotein ubiquitously expressed on the surface of 
various human cells including HeLa cell, plays an important role in cell 
adhesion and cell-cell interaction. With CD44 antibody and its FITC 
conjugated secondary antibody, we could evaluate the expression level 
of CD44 on the HeLa cells. After the cell surface modification including 
reduction of disulfides and coating with nanoparticles, polymers or both, 
the CD44 antibody can still anchor on the HeLa cell surfaces, which was 
confirmed by flow cytometry analysis (Figure 3.11). Another 
experiment was also conducted with macrophage cell line, RAW264.7, 
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which expresses CD11b (known as integrin alpha M) on the surface. We 
could obtain macrophage cells modified with polymer/nanoparticles and 
confirm the presence of the specific interaction between the CD11b 
antibody and macrophage cell surface (Figure 3.12). After the MSN-
coating, the viability or metabolism were retained. (Figure 3.13) The 
coated nanoparticles were distributed on cell surface for 9 hours in vitro 




Figure 3.6. Characterization of mesoporous silica nanoparticles (MSN) 
with maleimide functional moieties. a) TEM image of MSN. b) 
Distribution of hydrodynamic diameters of PEGylated nanoparticles 
with maleimide functional moieties (Mal-PEG-MSN) and without 
maleimide moieties (mPEG-MSN). Average diameters presented in the 
upper-left side of the plot. c,d) Absorption and emission spectra of FITC-







Figure 3.7. Cell surface modification with nanoparticles Confocal image 
of cells coated with fluorescent MSNs (left). Transmission electron 
microscopic image of MSNs attached on the cell surface (right).  
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Figure 3.8. Flow-cytometric analysis of nanoparticle attachment onto 
the cell membrane with mild reduction and conjugation for evaluating 
efficiency and rigidity of the attachment. MSN attachment depending on 
the functional moiety on MSN and TCEP treatment. Both TCEP 
treatment and the existence of maleimide functional groups 
(Mal+/TCEP+; red) enable efficient attachment of MSN to the cells. In 
the absence of TCEP treatment (Mal+/TCEP-; blue), fluorescent signal 
is lower than in the treated group. Without maleimide moieties on MSN 
(Mal-/TCEP+; dark green or Mal-/TCEP-; magenta), only few 






Figure 3.9. Measurement of fluorescent signal of MSN-attached cells, 
depending on the number of washing procedure. Measurement of 
fluorescent signal of MSN-adhered cells by (a) covalent conjugation or 
(b) non-specific adsorption. The fluorescent signals gradually decrease 
(black arrow), suggesting the detachment of MSN from the cells. All the 





Figure 3.10. Analysis on effect of surface modification on cell surface 
accessibility. (a) Flow cytometry analysis and (b-g) confocal images of 
suspended Hela cells stained with CellMask, before or after cell surface 
modification (b: negative control (N.Ctrl., without CellMask staining), 
c; positive control (P.Ctrl., treated with cell mask before surface 
modification), d; TCEP treated (TCEP),  e; Maleimide PEG coated cell 
(MalPEG), f; mesoporous silica nanoparticle coated cell (MSN), g; dual-




Figure 3.11. Analysis on the effect of surface modification on CD44-
antibody attachment to HeLa cell. (a) Flow cytometry analysis and (b-g) 
confocal images of suspended HeLa cells stained with CD44 antibody 
before and after cell surface modification (b: stained only with FITC 
conjugated secondary antibody (Sec.only), c; positive control (P.Ctrl., 
stained with CD44 antibody and FITC conjugated secondary antibody 
before surface modification), d; TCEP treated (stained with CD44 
antibody and FITC conjugated secondary antibody after TCEP 
treatment), e; Maleimide PEG coated cell (MalPEG), f; mesoporous 
silica nanoparticle coated cell (MSN), g; dual-coated cell (Dual, coated 
with MSN and MalPEG)). The fluorescent intensities of coated cells in 
flow cytometry analysis have a similar range of fluorescent intensities of 
uncoated cells, distinguished from negative control group.  
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Figure 3.12. (a) Viability evaluation of macrophage cell line (RAW 
264.7) depending on surface modification. (b-h) Analysis on the effect 
of surface modification on CD11b-antibody attachment to macrophage 
cell line (RAW 264.7). (b) Flow cytometry analysis and (c-h) confocal 
images of suspended RAW 264.7 stained with CD11b antibody before 
and after cell surface modification (c: negative control (N.Ctrl.), d; 
positive control (P.Ctrl., stained with FITC conjugated CD11b antibody 
before surface modification), e; TCEP treated (stained with FITC 
conjugated CD11b after TCEP treatment), f; Maleimide PEG coated cell 
(MalPEG), g; mesoporous silica nanoparticle coated cell (MSN), h; dual-
coated cell (Dual, coated with MSN and MalPEG)). The fluorescent 







Figure 3.13. Viability and proliferation of MSN-coated Hela cells. a) 
Plot of cell viability examined by Live/Dead assay. b) Cell metabolism 






Figure 3.14. Confocal microscope images of MSN decorated onto 
anchored HeLa cell at different incubation times. (a) In vitro images of 
the cells coated with fluorescent MSN after (i) 3, (ii) 6, (iii) 9, (iv) 12, 
and (v) 15 hours of the membrane coating. (top: bright field images, 
bottom: fluorescence images). (b) intravital images of MSN coated cells 
applied subcutaneously after (i) 2, (ii) 4, (iii) 6, (iv) 12, and (v) 18 hours 
of the membrane coating and injection. 
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3.3.2 Tracking and early stage imaging with attached NPs 
Using the MSN-coated cells, we performed two animal experiments 
including in vivo fluorescence imaging to track the location of cells and 
intra-vital microscopic imaging to visualize the early stages of cell 
therapy. Luciferase-producing HeLa cells were coated with near-infrared 
fluorescent MSNs and injected subcutaneously in the dorsal region of 
nude mice (Figure 3.15). Strong fluorescence from nanoparticles was 
observed where the cells were injected, co-localizing with the cellular 
luminescence, and it lasted for 8 days. Along with the early-stage intra-
vital imaging of cells, we studied localized drug delivery using the drug-
loaded MSNs to investigate the potential application of the MSN-coated 
cells for drug delivery.  
To study drug diffusion in vivo, rhodamine was loaded into the MSNs. 
We also used fluorescence correlation spectroscopy (FCS) technique to 
analyze the fluorescence from dye-laden MSNs (Figure 3.16 and Figure 
3.17). As shown in the Figure 3.16, the fluorescein or rhodamine signals 
have correlation curves which exhibit two distinct diffusion time spans. 
The fast diffusion region of the curve is indicative of free dye molecules, 
and the slow diffusion time coincides with that of Cy5 conjugated MSN. 
It can be inferred that that some of the fluorescein and rhodamine 
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molecules are released from MSNs and freely moving, and others are 
retained within MSN. The results of FCS and confocal imaging suggest 
that a considerable portion of rhodamine is present within the MSN. 
After coating HeLa cells with the rhodamine-loaded MSNs and 
confirming their coating with confocal microscope images (Figure 3.18), 
the cells were administered subcutaneously to nude mice and imaged 
with intra-vital confocal microscope. The red signal from the fluorescent 
MSNs delineated the round shapes of the coated surfaces, while green 
fluorescence derived from rhodamine diffused from the MSNs (Figure 
3.16). Initially, most of the rhodamine molecules were distributed in the 
HeLa cells, but as time progressed, they gradually diffused to 
neighboring immune cells, upper muscle fibers, and finally, lower 
muscle fibers (Figure 3.19 and Figure 3.20). The fluorescence signal 
diminished gradually, showing that rhodamine is steadily released and 
diffused from the injected area. The MSN-derived red signal and stability 
of MSN on the cell surface sustained over 18 h, clearly distinguishing 
the administered cells from the nearby immune cells and tissues (Figures 
3.14b, 3.20, and 3.21) Some of the cells were destroyed by immune 






Figure 3.15. Tracking of luciferase-producing HeLa cells coated with 
near infrared-fluorescent MSN subcutaneously injected in mice. a) 
Schematic drawing of the tracking experiments. b) Fluorescence and 
luminescence imaging of nude mouse after injection of Cy5.5-MSN 





Figure 3.16. Fluorescence correlation spectroscopy analysis on 
fluorescent dye-loaded MSN. (a) Autocorrelation curve of fluorescein 
(orange) and its fitting curve (red), autocorrelation curve of Cy5 
conjugated on MSN (cyan) and its fitting curve (blue), and cross-
correlation curve between fluorescein and Cy5 (gray) and its fitting curve 
(black). (b) Autocorrelation curve of rhodamine (orange) and its fitting 
curve (red), autocorrelation curve of Cy5 conjugated on MSN (cyan) and 
its fitting curve (blue), and cross-correlation curve between rhodamine 
and Cy5 (gray) and its fitting curve (black). The shaded region remarks 
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two distinct diffusion times of free dye (pale red) and loaded dye (sky-
blue). The autocorrelation curves of MSN and cross-correlation curves 
were fitted with single component normal diffusion model with triplet 
relaxation, and autocorrelation curves of fluorescein and rhodamine were 
fitted with double component normal diffusion model with triplet 
relaxation. The cross-correlation curves with the same diffusion time of 
MSN represents the bounded movement of fluorescein and rhodamine 







Figure 3.17. Release profiles of rhodamine, used as an alternative for 
small-molecule drugs, from rhodamine-loaded MSN, in function of time 




Figure 3.18. Confocal microscope images of dye-loaded MSN onto 
anchored HeLa cell membrane. (a) High magnified images, (i) bright 
field image, (ii) green fluorescent image from fluorescein locating in and 
around cell, (iii) Cy5 conjugated onto mesoporous silica, and (iv) merged 
image. (b) Low magnified image of the fluorescein loaded MSN, (i) 
bright field image, (ii) green as fluorescein, (iii) red as Cy5 on MSN, (iv) 
merged image. (c) Low magnified image of the rhodamine loaded MSN, 
(i) bright field image, (ii) green as rhodamine, and (iii) red as Cy5 on 
MSN. There is distinct colocalization on cell membrane of fluorescein 
and MSN, confirming that both fluorscein and Cy5 are present in MSN. 
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The red arrows point out the location of fluorescent dye molecules and 
MSN on membrane, and the white arrows point out the signals from dye 




Figure 3.19. Intra-vital confocal image showing the rhodamine delivery 
(a) Time-lapse intra-vital imaging showing early stage of applied cells 
coated with rhodamine(green)-containing MSNs (red) on the muscle 
under subcutaneous layer. XZ-planes of images of administered cells 
neighbouring tissues. (b) Time-dependent variation of the rhodamine 
concentration in each tissue. 
184 
 
Figure 3.20. Intra-vital confocal image of cells coated with fluorescent 
MSNs. Administered on the muscle under subcutaneous layer. XY-
planes of images of administered cells neighbouring tissues. Rhodamine 





Figure 3.21. Average intensity profiles of fluorescent signals from (a) 
Cy5 conjugated on MSN and (b) rhodamine diffusing into tissue, 
depending on depth and time. Variation of intensity signals of the Cy5-
MSN or rhodamine from treated HeLa cell. 
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3.3.3 Demonstration drug delivery and protection for cell therapy 
We demonstrated that dual coating of drug-loaded nanoparticles and 
protective polymer can enhance the activity of implanted cells. 
Dexamethasone immunosuppressant was loaded into MSNs and used 
with maleimide-conjugated PEG to coat luciferase-expressing HeLa 
cells. The cells were subcutaneously injected to mice with normal 
immunity. Cellular activity was evaluated based on luminescence of the 
implanted cells.  
As shown in Figure 3.22 the activity of the administered cells was 
reduced gradually due to the innate immune rejection. The PEG coated 
cells have slightly higher activity after two days of post-injection, and 
MSN-coated cells also showed enhanced activities, compared with the 
uncoated cells. It shows that the immunosuppressant and PEG coating 
can protect the implanted cells by chemically and physically respectively. 
We also prepared the cells which have both polymer and nanoparticle 
coating onto cell surface. Notably, the polymer/nanoparticle dual-coated 
cells showed highly increased activities at two days post-injection and 
maintained higher activities than the other groups, suggesting the 
synergistic effect of the multiple coatings (Figure 3.22).  
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Figure 3.22. Enhancement of cellular activity of implanted cells with 
drug delivery vehicle and protective polymer coatings. Maleimide-PEG 
was used for polymer coating, and immunosuppressant 
(dexamethasone)-loaded MSN for NP coating. (a) Luminescence image 
showing the cellular activity after transplantation of non-treated, MPEG-
coated, drug-loaded nanoparticle-coated, and MPEG/nano-particle dual-
coated HeLa cells. (b) Comparison of luminescence intensity obtained at 
the indicated time points after cell transplantation (n=5, *p<0.01 versus 
control group at the same time point).  
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3.3.4 Discussion 
Although there are previous reports which employ exogenous material 
on the cell surface for similar purposes, this method has definite 
advantages. The existing methods have limitations such as complicated 
preparation of coating materials, inability to coat individual cells, and the 
need for additional incubation time or microfluidic apparatus. Here in 
this section I would like to discuss the strength of our strategy in light of 
the existing coating methods.  
 
(1) Coating with positively charged polymers 
The slightly negative charge of the cellular membrane can be 
advantageous for the coating of positively charged polymers. Such idea 
is suitable for cell spheroids or cells attached on plate [4,9], but it is hard 
to coat the cells discretely in a suspension because it induces aggregation 
among cells. Using a large amount of positively charged polymers may 
reduce aggregation, but it can cause cytotoxicity to cells[43]. Our method 
can coat the biological cells separately with polymers or nanoparticles, 
preventing the aggregation of cells without adverse effect on a wide 
variety of cells.  
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(2) Coating with lipid derivatives or alkyl chain conjugated molecules 
The hydrophobic double layer of cellular membrane has been the target 
site of exogenous material. Derivatives of lipid, alkyl-chain, and 
cholesterol are used to incorporate functional materials on the cell 
surface.[25] However, it is difficult to dissolve the macromolecules 
decorated with hydrophobic chains in physiological medium. Multiple 
hydrophobic chains attached to proteins would disrupt protein structure. 
Furthermore, the hydrophobic moiety grafted materials easily penetrate 
the cellular membrane., causing potential off-target interactions. Our 
method using conjugation of maleimide functional group does not 
compromise the solubility of macromolecules and nanoparticles, and 
allows the attached materials to remain in their position,  
 
(3) Conjugation with amine-carboxylate functional group 
Although functional groups using amine and carboxylic acid can be 
utilized in cell surface modification[27-29], there are several advantages of 
thiol-maleimide labeling over amine labeling of cell surface proteins. 
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Many biomacromolecules, proteins, and small molecular drugs contain 
amine and carboxylate groups. Both efficiency and specificity of the 
reaction between coating materials and target functional groups on cell 
surface can be affected by the formation of undesired amide bonding. 
Conjugation of amine and carboxylate groups also necessitates an 
extraneous activation of carboxylate using sulfosuccinimidyl ester and 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC). After the 
amide bonding, byproducts including isourea or N-hydroxysuccinimide 
should also be removed. Conjugation between thiol and maleimide is 
free from byproducts or pre- or post-treatment processes and occurs in 
physiological condition. These features of thiol-maleimide coupling 
broaden the selection of the coating materials and drugs to deliver. We 
can apply various types of molecules and polymers to our surface 
modification method.  
 
(4) Introduction of reactive functional groups through glycoengineering 
Glycoengneering of the cells through metabolism of sialic acid or 
mannose is investigated to introduce desirable functional groups on the 
glycoproteins of cell surface.[30-32] However, these methods are time-
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consuming, taking several days to induce and confirm the expression of 
the target moieties onto cells. The mild reduction and subsequent 
conjugation require about half an hour. As this method does not require 
any additional stabilization and culturing steps, it will be suited to cell 
therapy using primary cells, such as cancer immunotherapy and 
hematopoietic stem cell transplantation. 
 
(5) Hydrogel coating using microfluidic channel 
Mooney group reported the unique method to coat the cell surface with 
hydrogel using microfluidic channels.[15] However, it is only operable 
with the experimental setup with rigorous optimization. In this 
manuscript, we focus on generally accessible and facile procedures using 
well-known bioconjugation. This method is expected to be accessible to 
broader audience, even for those who are not thoroughly skilled with 




In conclusion, we demonstrated a universal and innocuous method of cell 
surface modification to impart various properties of exogenous materials 
to cells. As this method does not have any adverse effect and require any 
additional stabilization and culture steps, it is expected to be suitable for 
cell therapy using primary cells, such as cancer immunotherapy and 
hematopoietic stem cell transplantation. An examination of surface 
ligand and targeting capacity will be necessary prior to practical 
therapeutic applications, considering the nonspecificity of reduction 
using TCEP. Given the need for incorporation of materials onto cell 
surfaces to monitor cell therapy and produce artificial tissue, this 
versatile technique is anticipated to play a key role in next-generation 
cell-based therapies. 
 
**Most of the contents of this chapter will be published in the article, 
“General and Facile Coating of Single Cells via Mild Reduction.” 
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초    록 
 
최소 침습시술은 최소한의 절개를 통해서 치료하여 염증과 
합병증을 줄이고 환자의 회복속도를 빠르게 하여 다양한 
분야의 침습적인 개방 수술을 대체하고 있다. 영상 장비와 
시술 도구의 개발과 함께, 고감도의 표지물질과 시술 부위를 
접합할 수 있는 무독성 접착제의 개발은 최소 침습 시술에서 
매우 중요하다. 고감도의 표지물질은 시술 부위를 정확하게 
파악 할 수 있도록 도와주고, 접착제는 시술 중에 발생한 손상 
부위를 접합하게 도와준다. 또한 다양한 수술요법을 대체하여 
각광을 받고 있는 세포 치료에서도 효과적인 고감도물질의 
표지는 세포의 이식과 세포치료의 치료 효과를 관찰하는데 
있어서 필요한 과정이다.  
 나노입자의 월등한 조영 효과와 생체적합성은 최소침습 
시술에서 필요한 영상화를 돕기에 적합한 물질이다. 
나노입자의 표면을 개질 하여 세포와 조직의 접착성을 
증대시키는 방법은 세포 치료 전의 효율적인 세포 표지와 
시술 중에 발생한 내부 상처 접합에 적합하다.  
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첫번째는 실시간 영상 장비에 적합하고 접착력이 우수한 
나노입자의 개발에 대한 연구로, 탄탈륨 옥사이드의 표면을 
개질하여 접착성질을 갖도록하고 실시간 영상 시술에서 
사용하는 X-선 투시영상, X-선 전산화 단층촬영, 초음파 
영상, 형광영상에서 이용 할 수 있도록 하였다. 탄탈륨 
옥사의드의 표면을 얇은 실리카로 코팅하여, 분산도와 
접착력을 확보하여, 기존에 개발되어 사용되고 있는 
시아노아크릴레이트를 기반한 접착제와 비교하여 비슷한 
수준의 접착력을 갖고있으며, 월등한 조영효과 또한 갖게 
되었다. 이는 세포독성과 염증반응에 취약한 합성고분자의 
단점을 또한 극복하여, 내부의 조직 장기에 사용하기에 
적합하다. 이 물질을 통해 실시간 영상과, 수술 전 암과 같은 
수술 부위를 표지하기에도 적합함을 동물실험을 통해 
보여주었다.  
   다음은 세포 치료를 위한 세포 표지에 대한 연구로, 약물이 
담재될 수 있고, 형광을 띌 수 있는 나노입자를 짧은 시간 
내로 손쉽게 세포의 표면에 부착할 수 있는 방법에 대한 
연구이다. 다공성 실리카 나노입자에 형광 물질을 부착하고, 
이를 세포 표면에 안정적으로 부착을 함으로써, 장기간의 
추적과 세밀한 관찰을 위한 생체내 현미경 영상을 할 수 있게 
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해 주었다. 기존의 세포 안에 흡수를 통해서 진행하는 표지 
방법에 비해서 빠른 시간내에 진행 할 수 있었고, 또한 약물을 
나노입자에 담재하여 국부적인 부위에 약물을 전달을 도모할 
수 있었다. 이 세포 표면의 개질을 통하여 세포 치료의 
초기단계에 대한 정보를 생검없이 실시간으로 보여주었고, 
약물의 전달에 대한 정보를 얻을 수 있었다. 추가적으로 
세포에 고분자와 면역억제제가 담재된 나노입자를 붙여, 
면역거부반응을 극복하며 세포의 활성을 더 증진 시킬수 
있었다.  
 
주요어: 나노입자, 다기능성, 약물 전달, 나노바이오기술, 
생의학적 응용, 최소침습시술, 접착제, 세포표면개질  
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